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ABSTRACT 
Many intracellular proteins are either conditionally or constitutively short-lived, with 
in vivo half-lives that can be as brief as a minute or so. The regulated and processive 
degradation of intracellular proteins is carried out largely by the ubiquitin (Ub)-proteasome 
system (UPS), in conjunction with molecular chaperones, autophagy, and lysosomal 
proteolysis. The N-end rule pathway, the first specific pathway of UPS to be discovered, 
relates the in vivo half-life of a protein to the identity of its N-terminal residue. Physiological 
functions of the N-end rule pathway are strikingly broad and continue to be discovered. 
In bacteria and in eukaryotic organelles mitochondria and chloroplasts all nascent proteins 
bear the pretranslationally formed N-terminal formyl-methionine (fMet) residue. What is the 
main biological function of this metabolically costly, transient, and not strictly essential 
modification of N-terminal Met, and why has Met formylation not been eliminated during 
bacterial evolution? One possibility is that the formyl groups of N-terminal Met in 
Nt-formylated bacterial proteins may signify a proteolytic role of Nt-formylation. My 
colleagues and I addressed this hypothesis experimentally, as described in Chapter 3 of this 
thesis. 
Among the multitude of biological functions of the mammalian Arg/N-end rule 
pathway are its roles in the brain, including the regulation of synaptic transmission and the 
regulation of brain’s G-protein circuits. This regulation is mediated, in part, by the its Ate1-
mediated arginylation branch of the Arg/N-end rule pathway. One role of the Ate1 
arginyltransferase (R-transferase) is to mediate the conditional degradation of three G-
protein down-regulators, Rgs4, Rgs5, and Rgs16.  Ate1-/- mice, which lack the Ate1 R-
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transferase, exhibit a variety of abnormal phenotypes. Chapter 4 describes our studies of 
neurological abnormalities in Ate1-/- mice (and also in mice that express Ate1 conditionally, 
upon the addition of doxycycline), with an emphasis on the propensity of these mice to 
epileptic seizures.  
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CHAPTER 1: 
INTRODUCTION TO THE N-END RULE PATHWAY 
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Many intracellular proteins are either conditionally or constitutively short-lived, with in vivo 
half-lives that can be as brief as a minute or so. In some cases, a proteolytic pathway targets and 
destroys a protein cotranslationally (1, 2). The regulated and processive degradation of intracellular 
proteins is carried out largely by the ubiquitin (Ub)-proteasome system (UPS), in conjunction with 
molecular chaperones, autophagy and lysosomal proteolysis. Other mediators of intracellular protein 
degradation include nonprocessive proteases such as caspases, calpains, and separases. These and 
other proteases can function as “upstream” components of the UPS, generating protein fragments 
that are targeted and degraded to short peptides by specific Ub-dependent proteases. Proteins that 
are damaged, misfolded, or otherwise abnormal are often recognized as such and selectively 
destroyed by the UPS. Physiologically important exceptions include conformationally perturbed 
proteins and/or their aggregates that are harmful but cannot be efficaciously repaired or removed. 
The resulting proteotoxicity underlies both aging and specific diseases, including neurodegeneration 
(3). 
One major role of the UPS is the regulation of proteins whose concentrations must vary with 
time and alterations in the state of a cell. Short in vivo half-lives of such proteins provide a way to 
generate their spatial gradients and to rapidly adjust their concentration or subunit composition 
through changes in the rate of their degradation. In addition, a short half-life of a protein would lead 
to a rapid decrease in its concentration upon cessation of its synthesis. This way, transcriptional or 
translational control of specific regulatory proteins can acquire switch-like properties, because a 
short-lived protein that is no longer made would not persist in a cell, in contrast to a metabolically 
stable protein. Proteolysis can also serve to activate or otherwise modulate protein molecules and 
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specific circuits. These and other properties of the UPS make it, among other things, a major 
regulator of gene expression (3).  
The field of Ub and regulated protein degradation was created in the 1980s, largely through 
the complementary discoveries by the laboratory of A. Hershko and the laboratory of A. Varshavsky. 
In 1978-1985, Hershko and colleagues analyzed Ub-mediated protein degradation in vitro (in cell 
extracts), including the isolation of enzymes that mediate Ub conjugation. In 1982–1990, 
Varshavsky and colleagues discovered the biological fundamentals of the UPS, including the first 
demonstration that the bulk of protein degradation in a living cell requires Ub conjugation and the 
identification of the first Ub-conjugating (E2) enzymes (see below for the enzymology of the UPS) 
with specific physiological functions, in the cell cycle (Cdc34 E2) and DNA repair (Rad6 E2). These 
advances initiated the understanding of the massive, multilevel involvement of the UPS in the 
regulation of the cell cycle and DNA damage response (3).  
In 1990, Varshavsky and colleagues identified and cloned an E3 ligase termed Ubr1 (see 
below for enzymology of the UPS), the first molecularly cloned and analyzed E3 Ub ligase. Together 
with the Rad6 E2 and Cdc34 E2 results, the cloning and characterization of the Ubr1 E3 opened up 
a particularly large field, as we now know that the mammalian genome encodes about 1,000 distinct 
E3s. The targeting of many distinct degrons in cellular proteins by this enormous diversity of specific 
E3 Ub ligases underlies the unprecedented functional reach of the Ub system (3). In 1986, 
Varshavsky and colleagues discovered the first primary degradation signals (degrons) in short-lived 
proteins. (Specific features of proteins that mark them for conjugation to Ub were presumed to exist, 
but their nature was a mystery.) These new signals included degrons that give rise to the N-end rule, 
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which relates the in vivo half-life of a protein to the identity of its N-terminal residue. The N-end 
rule pathway (it mediates the N-end rule) was the first specific pathway of the Ub system. Other 
foundational discoveries of the Varshavsky laboratory in the 1980s included the first substrate-linked 
poly-Ub chains, their specific topology, and their necessity for proteolysis; the subunit selectivity of 
protein degradation; the first physiological substrate of the UPS (the MATα2 repressor; before this 
advance, the UPS was examined using artificial substrates); and first genes that encode Ub precursors 
(linear poly-Ub and Ub fusions to specific ribosomal proteins. By the end of the 1980s, these and 
related studies by the Varshavsky laboratory had revealed the major biological functions of the UPS 
as well as the basis for its specificity, i. e., the first degradation signals in short-lived proteins (3). 
Enzymology of the UPS 
Ub is a 76-residue protein that mediates protein degradation through the enzymatic 
conjugation of Ub to proteins that contain primary degradation signals, called degrons (4). 
Ub-protein conjugation marks proteins for their recognition and degradation by the 26S proteasome, 
a processive, ATP-dependent protease. Ub is conjugated to proteins either as a single moiety or as a 
poly-Ub chain that is linked (in most cases) to the ε-amino group of an internal Lys residue in a 
substrate protein. Ub is a “secondary” degron, in that Ub is conjugated to proteins because they 
contain primary degradation signals. Ub has nonproteolytic functions as well (5).  
Ub is activated for conjugation to other proteins by a Ub-activating enzyme (E1), which 
couples ATP hydrolysis to the formation of a high-energy thioester bond between Gly76 of Ub and 
a specific Cys residue of E1 (6, 7). The E1-linked Ub moiety is moved, in a transesterification 
reaction, from E1 to a Cys residue of an Ub-conjugating enzyme (E2), and from there to a Lys residue 
  
5
of an ultimate acceptor protein, yielding an Ub-protein conjugate. This last step requires the 
participation of another component, called E3 ligase, which selects a protein for ubiquitylation 
through an interaction with its degron (7, 8). 
Repeated ubiquitylation at the same substrate’s site results in a poly-Ub chain. In these 
structures, the C-terminal Gly of one Ub is joined to an internal Lys of the adjacent Ub moiety, 
resulting in a chain of Ub-Ub conjugates containing two or more Ub moieties (9, 10). Ub has seven 
lysines; thus, a poly-Ub chain in which no Ub moiety has more than one Lys residue linked to another 
Ub moiety can have, a priori, any of the seven 'pure' topologies or a far greater number of 'mixed' 
topologies. The first poly-Ub chain to be discovered had its Ub moieties conjugated through the 
Lys48 residue of Ub (9). Other poly-Ub chains involve Lys63 or Lys29 of Ub (11, 12). A chain 
linked through the Lys63 residues of its Ub moieties has a role in a pathway of DNA repair (11). 
One function of the Lys48 linkage chain is to facilitate the degradation of the substrate by the 26S 
proteasome. 
The covalent bond between Ub and other proteins can be cleaved. There are multiple ATP 
independent proteases that recognize an Ub moiety and cleave at the Ub adduct junction (7, 13, 14). 
One cause of the multiplicity of deubiquitylases (DUBs) is the diversity of their targets, which 
include linear Ub fusions, Ub adducts with small nucleophiles such as glutathione, and also free or 
substrate linked poly-Ub chains (11, 12, 15, 16). The junctions in linear Ub adducts are structurally 
distinct from the junctions in branched Ub conjugates. Thus, some DUBs may have preferences for 
either linear or branched Ub adducts. In addition, a Ub conjugate can be spatially confined in a cell, 
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making it accessible only to some DUBs. For example, DUBs associated with the 26S proteasome 
have privileged access to a poly-Ub chain of a proteasome-bound substrate (7). 
The N-end rule pathway in eukaryotes 
In 1986, Varshavsky and colleagues discovered the first primary degradation signals in short-
lived proteins. These signals included degrons that give rise to the N-end rule, which relates the in 
vivo half-life of a protein to the identity of its N-terminal residue (17). In eukaryotes, the N-end rule 
pathway comprises two major branches, one of which is termed the Arg/N-end rule pathway. This 
branch involves the N-terminal deamidation (Nt-deamidation) and N-terminal arginylation 
(Nt-arginylation) of protein substrates, and also the recognition of specific unmodified N-terminal 
residues by the pathway’s E3 Ub ligases, termed N-recognins. The other branch of the N-end rule 
pathway is called the Ac/N-end rule pathway (18). It involves the cotranslational Nα-terminal 
acetylation (Nt-acetylation) of cellular proteins (19-21) whose N-termini bear either Met or the small 
uncharged residues Ala, Val, Ser, Thr, or Cys (22, 23). Nt-acetylated proteins are targeted for 
regulated degradation by specific Ub ligases (called Ac/N-recognins) of the Ac/N-end rule pathway 
(18). Approximately 90% of human proteins are cotranslationally Nt-acetylated (19). Many, possibly 
most, Nt-acetylated proteins contain Ac/N-degrons (18, 24-26). 
In the Arg/N-end rule pathway, the N-terminal Arg, Lys, His, Leu, Phe, Tyr, Trp, Ile, Asp, 
Glu, Asn, Gln, and Cys residues comprise the main determinants of N-degrons. Among these N-
degrons, the unmodified basic (Arg, Lys, His) and bulky hydrophobic (Leu, Phe, Tyr, Trp, Ile) N-
terminal residues are recognized directly by cognate E3 N-recognins. These E3s contain highly 
spalogous (spatially similar (27)) ∼80-residue regions called UBR domains or Type-1 binding sites 
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(28). Folded around three zinc ions, a UBR domain binds to N-terminal Arg, Lys, or His, the Type-
1 primary destabilizing residues of N-end rule substrates. Another region of UBR-type N-recognins, 
called the Type-2 binding site, recognizes N-terminal Leu, Phe, Tyr, Trp, or Ile, which are called the 
Type-2 primary destabilizing residues (28-30).  
In contrast to N-terminal Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile, the N-terminal Asp, Glu, 
Asn, Gln, and Cys function as destabilizing residues through their preliminary chemical 
modifications. One of these modifications is Nt-arginylation. Arg-tRNA-protein transferase 
(R-transferase) conjugates Arg to N-terminal Asp, Glu, or (oxidized) Cys of proteins or short 
peptides, with Arg-tRNA as the cosubstrate and the donor of Arg. R-transferases are encoded by 
Ate1 and its sequelogs from yeast to mammals but are absent from examined prokaryotes (31-33). 
In contrast to N-terminal Asp, Glu and oxidized Cys, the N-terminal Asn and Gln residues cannot 
be arginylated by R-transferase. However, the Arg/N-end rule pathway contains specific N-terminal 
amidases (Nt-amidases) that convert N-terminal Asn and Gln to Asp and Glu, respectively, followed 
by their Nt-arginylation (34-37). N-terminal Asp, Glu, Asn, Gln, and Cys that are targeted by the 
Arg/N-end rule pathway are termed “secondary” or “tertiary” destabilizing residues, depending on 
the number of specific steps that precede their targeting by N-recognins (31, 36, 38, 39).  
The substrate range of the Arg/N-end rule pathway was recently expanded as a result of the 
discovery that both S. cerevisiae Ubr1 and mammalian Ubr1 and Ubr2 can recognize the N-termini 
of Met-Ф proteins through their unacetylated N-terminal Met residues, resulting in the processive 
degradation of these proteins. (A Met-Ф protein bears N-terminal Met followed by a large 
hydrophobic [Ф] non-Met residue, i.e., Leu, Phe, Tyr, Trp or Ile.) On the other hand, Nt-acetylation 
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would convert a MetФ/N-degron into an AcMetФ/N-degron, and thereby would shift the targeting 
of the resulting Ac-Met-Ф protein to the Ac/N-end rule pathway. The resulting functional 
complementarity between the Arg/N-end rule and the Ac/N-end rule pathways makes possible the 
proteolysis-mediated control of Met-Ф proteins irrespective of the extent of their Nt-acetylation (24, 
25).  
An N-degron can be produced through a cotranslational or posttranslational proteolytic 
cleavage. Ribosome-associated Met-aminopeptidases cleave off the Met residue from the 
N-terminus of a nascent protein if and only if the residue at position 2, to become N-terminal 
after cleavage, is not larger than Val (22). Of the 13 residues that are destabilizing in the 
mammalian Arg/N-end rule pathway, only Cys can be made N-terminal by 
Met-aminopeptidases. The second-position Ala, Val, Ser, Thr, or Cys can also be made N-
terminal by Met-aminopeptidases. These residues are usually Nt-acetylated and are a part of the 
Ac/N-end rule pathway. If N-terminal Met is followed by a residue larger than Val, this Met is 
not cleaved off, and is usually Nt-acetylated. In these nascent proteins, their N-terminal Met is, 
most cases, cotranslationally Nt-acetylated, thereby generating Ac/N-degrons recognized the 
Ac/N-end rule pathway (1). 
N-degrons of the Arg/N-end rule pathway can also be produced by non-MetAP 
nonprocessive proteases, including caspases (40, 41), calpains (42), separase (43), taspase (44), 
MALT1 protease (45), γ-secretase (46), proteinase-3 (PR3) (47), viral proteases (48, 49), and 
other such proteases as well. Thus, operationally, these proteases function as upstream 
components of the N-end rule pathway, generating its substrates, which comprise C-terminal 
  
9
fragments of naturally cleaved proteins (29, 38). In sum, a majority of cellular proteins can be 
targeted for regulated degradation by the Arg/N-end rule and Ac/N-end rule pathways, which can 
act, on a given protein, either separately or together, depending on the protein’s N-terminal 
sequence and the state of its modification.  
Physiological functions of the N-end rule pathway are strikingly broad and continue to be 
discovered. Regulated degradation of proteins by the eukaryotic Arg/N-end rule pathway 
mediates the sensing of heme, NO, oxygen, and short peptides; the selective elimination of 
misfolded proteins; the regulation of DNA repair (at least in part through the degradation of 
Mgt1, a DNA repair protein); the cohesion/segregation of chromosomes (through the degradation 
of a subunit of cohesin); the signaling by transmembrane receptors (through the degradation of 
the G-protein regulators Rgs4, Rgs5, and Rgs16); the control of peptide import (through the 
degradation of Cup9, the import's transcriptional repressor); the regulation of apoptosis, meiosis, 
viral and bacterial infections, fat metabolism, cell migration, actin filaments, cardiovascular 
development, spermatogenesis, neurogenesis, and memory; the functioning of adult organs, 
including the brain, muscle, testis, and pancreas; and the regulation of leaf and shoot 
development, leaf senescence, and seed germination in plants (18, 29, 31, 33, 35, 38, 48-63). 
Mutations in UBR1, an E3 N-recognin of the human Arg/N-end rule pathway, cause Johanson–
Blizzard syndrome (JBS). It comprises, among other defects, physical malformations, 
insufficiency and inflammation of the exocrine pancreas, frequent mental retardation, and 
deafness (52). An N-recognin such as mammalian UBR2 can also function to protect specific 
proteins from degradation (64). The Ac/N-end rule pathway mediates, among other things, 
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protein quality control and the regulation of in vivo stoichiometry of proteins that form 
multisubunit complexes (26). 
Regulation of G proteins and the N-end rule pathway 
As mentioned in the preceding section, the functions of the mammalian Arg/N-end rule 
pathway include the sensing of NO and oxygen and the regulation of specific G proteins that are 
coupled to transmembrane receptors. These processes involve the NO/O2-dependent degradation 
of Rgs4, Rgs5, and Rgs16, a set of G-protein regulators (31, 33, 39). The conditional 
Nt-arginylation and degradation of these RGS proteins by the Arg/N-end rule pathway alters the 
activity of cognate G-protein circuits (31, 33). Rgs4 is an inhibitor of tubulogenesis, a process 
that underlies the development and homeostasis of blood vessels and other tubular structures, 
such as those in the mammary gland, kidney and lung (65). Rgs4 and Rgs16 block signaling by 
the vascular endothelial growth factor (VEGF), and Rgs5 regulates vessel remodeling during 
neovascularization (66). Rgs4 is also known to be a negative modulator of the myocardial 
hypertrophic response (67). The rate of degradation of Rgs4, largely by the Arg/N-end rule 
pathway, influences other physiological and pathophysiological processes, including the 
invasiveness of breast cancer, responses of neurons to opiates, and responses of cells in culture to 
fluxes of calcium ions (68, 69).  
The Cre recombinase-induced postnatal loss of the Ate1 R-transferase and Nt-
arginylation in adult mice leads to a more than 10-fold increase in the level of the metabolically 
stabilized Rgs4 in the resulting Ate1-deficient mice, suggesting a major decrease in signaling by 
Rgs4-regulated G proteins (70). The loss of Nt-arginylation results in a number of phenotypic 
  
11
alterations in Ate1-deficient mice. Studies described in this thesis explore, in particular, the 
physiology of Ate1 deficiency and the upregulation of Rgs4, Rgs5, and Rgs16 in Ate1-deficient 
mice. 
In addition, the two branches of the N-end rule pathway, Ac/N-end rule and Arg/N-end 
rule pathways, were recently found to regulate Rgs2. This regulator of G proteins lowers blood 
pressure by decreasing signaling through Gαq. Human patients expressing Met-Leu-Rgs2 (ML-
Rgs2) or Met-Arg-Rgs2 (MR-Rgs2) are hypertensive relative to people expressing wild-type 
Met-Gln-Rgs2 (MQ-Rgs2). Park and colleagues found that wild-type MQ-Rgs2 and its mutant, 
MR-Rgs2, were destroyed by the Ac/N-end rule pathway, which recognizes Nt-acetylated 
proteins (24). The shortest-lived mutant, ML-Rgs2, was targeted by both the Ac/N-end rule and 
Arg/N-end rule pathways. The latter pathway recognizes unacetylated N-terminal residues. Thus, 
the Nt-acetylated Ac-MX-Rgs2 (X = Arg, Gln, Leu) proteins are specific substrates of the 
mammalian Ac/N-end rule pathway. Furthermore, the Ac/N-degron of Ac-MQ-Rgs2 was 
conditional, and Teb4, an endoplasmic reticulum (ER) membrane-embedded ubiquitin ligase, 
was able to regulate G protein signaling by targeting Ac-MX-Rgs2 proteins for degradation 
through their Nα-terminal acetyl group. 
The N-end rule pathway in bacteria 
Although bacteria lack a bona fide Ub system, they contain a Ub-independent version of 
the N-end rule pathway, termed the Leu/N-end rule pathway. The Leu/N-end rule pathway was 
discovered in 1991 by the Varshavsky laboratory (71), and was characterized in gram-negative 
bacteria Escherichia coli and Vibrio vulnificus (50, 72). It comprises the following components. 
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(1) ClpAP, a proteasome-like, ATP-dependent protease;  
(2) ClpS, the 12-kDa N-recognin of the Leu/N-end rule pathway that binds to N-terminal 
Leu, Phe, Trp or Tyr and delivers N-end rule substrates to the ClpAP protease (50, 73-76);  
(3) Aat, an L/F-transferase that uses Leu-tRNA or Phe-tRNA as a cosubstrate to 
conjugate largely Leu (and occasionally Phe) to the N-termini of proteins bearing N-terminal Lys 
or Arg, the secondary destabilizing residues of the Leu/N-end rule pathway;  
(4) Bpt, an L-transferase that uses Leu-tRNA to conjugate Leu to N-terminal Asp, Glu, 
and (possibly) oxidized Cys (1). 
V. vulnificus contains both the Aat and Bpt L-transferases, while E. coli contains only 
Aat. Therefore N-terminal Arg, Lys, Asp and Glu are secondary destabilizing residues in 
V. vulnificus, whereas in E. coli the N-terminal Asp and Glu are stabilizing (“non-destabilizing”) 
residues (72). In V. vulnificus, the two L-transferases are encoded by the aat-bpt operon, but in 
several other gram-negative bacteria these two genes are unlinked, and some gram-negatives 
lack one or the other of these L-transferases (for example, E. coli lacks Bpt) (1).  
Two physiological substrates of the Leu/N-end rule pathway have been described so far, 
in addition to a more tentatively identified (potential) substrate (76, 77), One of these substrates 
is Dps, an 18-kDa DNA-binding protein that compacts the nucleoid of E. coli in starving cells, 
forming highly ordered, crystal-like structures. An unknown protease removes 5 residues from 
the initial N-terminus of Dps, generating N-terminal Leu and thereby making Dps a short-lived 
N-end rule substrate. The other identified N-end rule substrate is the E. coli YgjG putrescine-
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aminotransferase (PATase). It is targeted for degradation by the Leu/N-end rule pathway 
through a (so far) unique route that requires Nt-leucylation, by the Aat L/F-transferase, of the 
(initial) N-terminal Met residue of PATase (77). The “non-cognate” specificity of L/F-
transferase, in this setting, remains to be confirmed. One possibility is that the active site of the 
Aat L/F-transferase might be able to accommodate the N-terminal Met of a substrate for its 
conjugation to Leu if the substrate's second residue is, for example, Asn, a small hydrophilic 
residue (1). 
Both gram-negative and gram-positive bacteria use the Nt-formylated Met residue (fMet) 
to initiate the synthesis of a polypeptide chain. The resulting N-terminal fMet of nascent 
bacterial proteins is cotranslationally deformylated by a ribosome-bound deformylase (78). In the 
next two chapters of this thesis, I will describe and discuss experimental data that support the 
hypothesis about fMet-based degradation signals, termed fMet/N-degrons. 
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Figure 1.1. The ubiquitin-proteasome system. Ub-protein conjugation marks proteins for their 
recognition and degradation by the 26S proteasome, a processive, ATP-dependent protease. Ub is 
conjugated to proteins as a poly-Ub chain that is linked to the ε-amino group of an internal Lys 
residue in a substrate protein. Ub is activated for conjugation to other proteins by an Ub-activating 
enzyme (E1), which couples ATP hydrolysis to the formation of a high-energy thioester bond 
between Gly76 of Ub and a specific Cys residue of E1 (6, 7). The E1-linked Ub moiety is moved, in 
a transesterification reaction, from E1 to a Cys residue of an Ub-conjugating enzyme (E2), and from 
there to a Lys residue of an ultimate acceptor protein, yielding an Ub-protein conjugate. This last 
step requires the participation of another component, called E3 Ub ligase, which selects a protein for 
ubiquitylation through an interaction with its degradation signal. 
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Figure 1.2. The Arg/N-end rule pathway in mammals. An N-degron can be produced through a 
cotranslational or posttranslational proteolytic cleavage by the methionine aminopeptidases 
(MetAPs), caspases, calpains, or other non-possessive proteases. N-terminal Arg, Lys, His, Leu, Phe, 
Tyr, Trp, Ile, Asp, Glu, Asn, Gln, and Cys comprise the main determinants of N-degrons. The 
unmodified Type-1 basic (Arg, Lys, His) and Type-2 bulky hydrophobic (Leu, Phe, Tyr, Trp, Ile) 
N-terminal residues are recognized directly by cognate E3 N-recognins Ubr1, Ubr2, Ubr4, and Ubr5. 
The N-terminal Asp, Glu, Asn, Gln, and Cys function as destabilizing residues through their 
preliminary modifications. Arg-tRNA-protein transferase (R-transferase) conjugates Arg to N-
terminal Asp, Glu, or oxidized Cys of proteins or short peptides, with Arg-tRNA as the cosubstrate 
and the donor of Arg. The N-terminal Asn and Gln residues are converted by the N-terminal 
amidases to Asp and Glu. N-terminal Asp, Glu, Asn, Gln, and Cys that are targeted by the Arg/N-
end rule pathway are termed “secondary” or “tertiary” destabilizing residues, depending on the 
number of specific steps that precede their targeting by N-recognins. 
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Figure 1.3 The bacterial Leu/N-end rule pathway. (A) In Escherichia coli, Aat, an L/F-
transferase, uses Leu-tRNA or Phe-tRNA as a cosubstrate to conjugate largely Leu (and 
occasionally Phe) to the N-termini of proteins bearing N-terminal Lys or Arg, the secondary 
destabilizing residues of the Leu/N-end rule pathway. ClpS, the 12-kDa N-recognin of the 
Leu/N-end rule pathway that binds to N-terminal Leu, Phe, Trp or Tyr and delivers N-end rule 
substrates to the ClpAP protease. (B) In V. vulnificus, in addition to the machinery E. coli 
possesses, there is also Bpt, an L-transferase that uses Leu-tRNA to conjugate Leu to N-terminal 
Asp, Glu, and (possibly) oxidized Cys. 
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Abstract 
In bacteria, all nascent proteins bear the pretranslationally formed N-terminal 
formyl-methionine (fMet) residue. The fMet residue is cotranslationally deformylated by a 
ribosome-associated deformylase. The formylation of N-terminal Met in bacterial proteins 
is not essential for either translation or cell viability. Moreover, protein synthesis by the 
cytosolic ribosomes of eukaryotes does not involve the formylation of N-terminal Met. 
What, then, is the main biological function of this metabolically costly, transient, and not 
strictly essential modification of N-terminal Met, and why has Met formylation not been 
eliminated during bacterial evolution? One possibility is that the similarity of the formyl 
and acetyl groups, their identical locations in N-terminally formylated (Nt-formylated) and 
Nt-acetylated proteins, and the recently discovered proteolytic function of Nt-acetylation in 
eukaryotes might also signify a proteolytic role of Nt-formylation in bacteria. We 
addressed this hypothesis about fMet-based degradation signals, termed fMet/N-degrons, 
using specific E. coli mutants, pulse-chase degradation assays, and protein reporters whose 
deformylation was altered, through site-directed mutagenesis, to be either rapid or 
relatively slow. Our findings strongly suggest that the formylated N-terminal fMet can act 
as a degradation signal, largely a cotranslational one. One likely function of fMet/N-
degrons is the control of protein quality. In bacteria, the rate of polypeptide chain 
elongation is nearly an order of magnitude higher than in eukaryotes. We suggest that the 
faster emergence of nascent proteins from bacterial ribosomes is one mechanistic and 
evolutionary reason for the pretranslational design of bacterial fMet/N-degrons, in contrast 
to the cotranslational design of analogous Ac/N-degrons in eukaryotes. 
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Introduction 
Nascent polypeptides bear the N-terminal Met residue, encoded by the AUG 
initiation codon. In bacteria and in eukaryotic organelles mitochondria and chloroplasts 
(remote descendants of bacteria), this Met is Nα-terminally formylated (Nt-formylated) 
through a “pretranslational” mechanism. Formyltransferase (FMT) uses 10-
formyltetrahydrofolate to formylate the α-amino group of the Met moiety in the initiator 
Met-tRNA୧୑ୣ୲ [1-8]. The resulting formyl-Met (fMet) becomes the first residue of a 
nascent polypeptide that emerges from a bacterial ribosome (Fig. 1A) [9-13]. The formyl 
moiety of N-terminal fMet is cotranslationally removed by peptide deformylase (PDF), 
which is reversibly bound to the ribosome near the exit from the ribosomal tunnel (Fig. 
1B) [4, 14-27]. A ribosome-associated chaperone called trigger factor (TF) interacts with 
proteins emerging from the tunnel [28-42]. The signal recognition particle (SRP) also 
binds to some nascent proteins, recognizing specific sequence motifs (signal sequences) 
and directing SRP-associated proteins for translocation through the inner membrane [42-
45].  
Once N-terminal fMet of a nascent protein is deformylated by PDF, the resulting 
Met can be cleaved off by Met-aminopeptidase (MetAP) (Fig. 1B). The removal of 
(deformylated) Met by MetAP requires that a residue at position 2, to be made 
N-terminal by the cleavage, is not larger than Val [26, 46-48]. The Escherichia coli PDF 
deformylase binds to the 50S ribosomal subunit in part through contacts with the L22 
ribosomal protein [23, 26]. PDF and MetAP act sequentially in their cotranslational 
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processing of nascent proteins and compete with each other for interactions with their 
overlapping binding sites on the ribosome near the tunnel’s exit [26]. 
High-affinity interactions of the TF chaperone with a nascent protein begin to take 
place after the first ~100 residues of the protein have been synthesized [28]. Deformylation 
of N-terminal fMet by PDF (Fig. 1B) is impeded in cells engineered to overproduce TF 
[28]. Consequently, it is likely that in wild-type cells, by the time a nascent protein 
becomes larger than ~100 residues, i.e., shortly before the binding of TF to this protein 
[28], its N-terminal fMet had already been, in most cases, deformylated by the 
ribosome-associated PDF. The rate of chain elongation by bacterial ribosomes in vivo at 
37°C is 10-20 residues/sec [49-52]. Thus, the in vivo lifespan of the formyl group, from the 
moment fMet becomes the first residue of a newly initiated protein to the moment of fMet 
deformylation, is usually less than a minute. Given the delay in high-affinity binding of TF 
to a nascent protein [28], its first ~100 residues, which require 5-10 sec to be made, may be 
unassociated, during a fraction of those 5-10 sec, with any chaperone. 
Although the fMet moiety of bacterial fMet-tRNA୧୑ୣ୲ interacts with the initiation 
factor IF2 and thereby contributes to the efficacy of translation initiation [5, 7, 53-55], the 
formylation of N-terminal Met is not strictly essential for protein synthesis and cell 
viability. For example, E. coli fmt mutants lacking formyltransferase are viable. Their 
abnormal phenotypes include slow growth and hypersensitivity to stresses [3, 4, 7]. In 
Salmonella enterica, the slow growth of fmt mutants can be alleviated, during serial 
passaging, through the emergence of mutants that overexpress the initiator tRNA୧୑ୣ୲ [56]. 
In Pseudomonas aeruginosa, an engineered overexpression of IF2 can alleviate slow 
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growth of fmt mutants in minimal media [57]. Moreover, in P. aeroginosa and some 
other bacteria (other than E. coli), the ablation of fmt results in cells whose growth rates 
in rich media are nearly identical to those of wild-type cells [57, 58].  
In contrast, deformylation of the bulk of N-terminal fMet in nascent proteins is 
required for cell viability. Either a strong inhibition of PDF by the antibiotic actinonin or 
ablation of the PDF-encoding def gene are lethal, because MetAP is unable to cleave off 
the formyl-bearing N-terminal fMet [46]. (The inability to remove N-terminal Met leads 
to cell death in part because specific non-Met residues, e.g., Thr, must become N-
terminal in some essential enzymes, in which these non-Met residues are parts of 
enzymes’ active sites [59].) However, double fmt def mutants, which lack both FMT and 
PDF and therefore can neither deformylate fMet nor formylate it in the first place, are 
viable, with phenotypes similar to those of single fmt mutants [23].  
In eukaryotes, protein synthesis by the cytosolic ribosomes does not involve the 
formylation of Met, indicating that it was feasible, during evolution, to either lose the 
formylation of Met or not to acquire it in the first place. (It is unknown whether 
formylation of Met was a part of translation in the last common ancestor of extant 
organisms.) Innate immune responses involve the recognition of Nt-formylated bacterial 
proteins and short peptides. They are present in infected animals at high enough levels to 
act as chemoattractants for macrophages and neutrophils [60, 61]. Consequently, the 
formylation of Met can be a detriment to bacterial fitness. 
Given these properties of fMet, why do all examined wild-type bacteria contain 
formyltransferase, deformylase, and use fMet, rather than Met, to initiate translation? 
Why has this pervasive, metabolically costly, transient, and not strictly essential 
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modification of N-terminal Met not been eliminated during bacterial evolution? This 
conundrum suggested to us that the main biological function of fMet, the one that 
underlies the universal presence of N-terminal fMet in extant wild-type bacteria, 
remained to be discovered. 
Previous work identified the N-terminus of an intracellular protein as the site of 
degradation signals (degrons [62]) that are targeted by the N-end rule pathway (Fig. S1). 
This pathway is a set of proteolytic systems whose unifying feature is their ability to 
recognize proteins containing N-terminal degradation signals called N-degrons and to 
cause the processive degradation of such proteins by the 26S proteasome in eukaryotes 
(Fig. S1A, B) [63-74] or by the proteasome-like protease ClpAP in bacteria (Fig. S1C, D) 
[75-80]. In eukaryotes, N-degrons can also mediate the degradation of specific proteins 
(and their noncovalently bound protein ligands) by autophagy, as distinguished from the 
proteasome [74]. The main determinant of an N-degron is either an unmodified or 
chemically modified “destabilizing” N-terminal residue of a protein. Recognition 
components of the N-end rule pathway are called N-recognins. In eukaryotes, N-recognins 
are specific E3 ubiquitin (Ub) ligases that recognize N-degrons and polyubiquitylate 
proteins bearing them [71-73]. Bacteria lack the bona fide Ub system. The bacterial N-end 
rule pathway employs the ClpS N-recognin (but no ubiquitylation) to deliver targeted N-
end rule substrates to the ClpAP protease (Fig. S1C, D) [75, 76, 79-93].  
In eukaryotes, the N-end rule pathway consists of two branches. One of these 
branches, called the Arg/N-end rule pathway, targets proteins bearing N-terminal Arg, Lys, 
His, Leu, Phe, Tyr, Trp, Ile, Asn, Gln, Asp, Glu, and Cys (Fig. 1B) [63, 65, 71-73, 94-97]. 
This pathway can also target unmodified N-terminal Met, if Met is followed by a bulky 
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hydrophobic residue (Fig. S1A). Among these N-terminal residues, Asn, Gln, Asp, Glu, 
and Cys are destabilizing owing to their preliminary enzymatic modifications, which 
include N-terminal deamidation (Nt-deamidation) of Asn and Gln and Nt-arginylation of 
Asp, Glu and Cys (the latter after its conditional oxidation) [66, 96, 98, 99]. The substrate 
specificity of the bacterial N-end rule pathway is similar to the targeting range of the 
Arg/N-end rule pathway but is not as broad (Fig. S1C, D) [71, 77, 78].  
The other branch of the eukaryotic N-end rule pathway is called the Ac/N-end rule 
pathway. It recognizes proteins through their Nα-terminally acetylated (Nt-acetylated) 
residues (Fig. S1B) [67-70]. The degrons and N-recognins of the Ac/N-end rule pathway 
are called Ac/N-degrons and Ac/N-recognins, respectively. Nt-acetylation of eukaryotic 
proteins is largely cotranslational, being mediated by ribosome-associated Nt-acetylases 
[100-102]. At least 60% and about 90% of proteins are Nt-acetylated in the yeast S. 
cerevisiae and in human cells, respectively [103-106]. Nt-acetylation is apparently 
irreversible, i.e., a protein molecule acquires the Nα-acetyl group largely at birth and retains 
this group for the rest of that molecule’s lifetime in a cell. While Nt-acetylation also takes 
place in bacteria, it involves less than 10% of bacterial proteins and can occur only after the 
PDF-mediated deformylation of N-terminal fMet [107, 108]. Nothing is known about 
whether or not a version of the Ac/N-end rule pathway exists in bacteria as well. 
The acetyl and formyl groups differ by the CH3 moiety vs. the hydrogen atom. It 
occurred to us that the similarity of acetyl and formyl, their identical locations in 
Nt-acetylated and Nt-formylated proteins, and the recently discovered proteolytic function 
of Nt-acetylation in eukaryotes [67-71] might also signify the proteolytic role of 
Nt-formylation in bacteria, despite the transiency of the formyl group in fMet of nascent 
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bacterial proteins. We proposed this hypothesis in 2010 [67] and carried out experiments 
to verify it in the present study.  
The evidence below (Figs. 2-4) strongly suggests that N-terminal fMet can act as 
an N-degron, termed fMet/N-degron. In bacteria, the rate of polypeptide chain elongation 
is nearly an order of magnitude higher than in eukaryotes. We suggest that the faster 
emergence of nascent proteins from bacterial ribosomes may be the mechanistic and 
evolutionary reason for the pretranslational design of bacterial fMet/N-degrons (Fig. 1A), 
in contrast to the cotranslational design of Ac/N-degrons in eukaryotes (Fig. S1B). By 
analogy with Ac/N-degrons [67-71], one function of bacterial fMet/N-degrons is likely to 
be the quality control of both nascent proteins and just released, newly formed proteins. 
Specifically, fMet/N-degrons are envisioned to augment the quality of bacterial proteome 
through a preferential and largely cotranslational degradation of Nt-formylated misfolded 
proteins. This would happen at the price of eliminating a subset of normal proteins as 
well, given the stochasticity of both the PDF-mediated deformylation of fMet and the 
alternative, competing process of targeting and destroying Nt-formylated proteins 
through their fMet/N-degrons. 
 
Results 
Inhibition of fMet deformylation decreases the levels of larger pulse-labeled proteins 
Wild-type E. coli were pulse-labeled for 1 min at 37°C with 35S-
methionine/cysteine in (Fig. 2A). The pulse was followed by a chase (in the presence of 
translation inhibitor chloramphenicol), preparation of cell extracts, SDS-PAGE, and 
autoradiography. Actinonin, a specific inhibitor of PDF, was either absent or present, at 
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indicated concentrations, throughout pulse chases. The inhibition of fMet deformylation 
by actinonin was found to cause a significant decrease in the levels of larger (more than 
~35 kDa) 35S-labeled proteins and a concomitant increase of smaller (less than ~20 kDa) 
proteins (Fig. 2A).  
Additional 35S-pulse-chases (this time in the absence of chloramphenicol) with 
wild-type vs. formyltransferase-lacking fmt E. coli showed that the above effect of 
actinonin required the formylation of N-terminal Met, because 35S-protein patterns in fmt 
cells were essentially the same in the presence or absence of actinonin (Fig. 2B). These 
results (Fig. 2) were consistent with the fMet/N-degron hypothesis (Fig. 1C-E), as it 
predicts that the probability of destruction of an fMet-bearing nascent protein would be 
higher, on average, for a larger protein, because its polypeptide chain, i.e., its ribosome-
associated peptidyl-tRNA, would dwell in the vicinity of a translating ribosome for a 
longer time than would be the case for a smaller fMet-bearing nascent protein. The 
postulated fMet/N-recognin/protease (Fig. 1E) or at least its fMet/N-recognin part is 
envisioned to be reversibly associated with the ribosomes (see Discussion). Thus, the 
probability of capture of larger Nt-formylated proteins by this protease would be higher 
than the corresponding probability for smaller fMet-bearing nascent proteins, because the 
latter would be released sooner and diffuse into the bulk solvent, i.e., into regions with 
(presumably) lower levels of the fMet/N-recognin/protease. 
An alternative interpretation of these results is that actinonin might increase the 
probability of premature chain termination. This increase would lead to a lower relative 
abundance of larger (as compared to smaller) pulse-labeled proteins in the presence of 
actinonin, thereby accounting for our results (Fig. 2) without invoking a preferential 
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degradation of these proteins. However, this interpretation was made unlikely by the fact 
that the observed effect of actinonin required the formylated state of N-terminal Met, i.e. 
this effect of actinonin was not observed with fmt cells, in contrast to wild-type cells (Fig. 
2B). 
 
Higher levels of a protein reporter in formylation-lacking mutants 
One prediction of the fMet/N-degron hypothesis is as follows: even in the case of a 
nascent protein whose N-terminal amino acid sequence makes it an efficacious PDF 
substrate, some molecules of this protein would still be expected to be destroyed through 
the protein’s fMet/N-degron, given the stochasticity of deformylation of N-terminal fMet 
by PDF and the alternative, competing process of targeting an fMet-bearing protein for 
degradation (Fig. 1C-E). Consequently, the ribosome-associated PDF deformylase would 
be expected to occasionally lose the competition for N-terminal fMet to a postulated 
fMet/N-recognin/protease, resulting in the degradation of a targeted nascent protein. The 
kinetic advantage of PDF may be decreased if a nascent N-terminal segment of a protein 
would be either unfolded (with N-terminal fMet partly obscured within a “molten globule”) 
or misfolded in a way that decreases the time-averaged solvent exposure of N-terminal 
fMet (Fig. 1C-E and Discussion). If so, the steady-state level of such a protein would be 
expected to increase in formyltransferase-lacking fmt mutants.  
We addressed this prediction through a reporter bearing the N-terminal sequence of 
a protein called D2. Earlier studies of D2 protein in plant chloroplasts, by Giglione, 
Meinnel and colleagues [109, 110], were relevant to experiments of the present study. 
Although our 2010 hypothesis about fMet as a degradation signal [67] was cited by 
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Giglione and colleagues [110], they did not interpret their findings with D2 protein in 
terms of fMet/N-degrons. In contrast, the results below, using the N-terminal segment of 
D2 as a part of protein reporters (Figs. 3 and 4), strongly suggest that the data by Giglione 
et al. [109, 110] can be interpreted, in hindsight, as a likely example of protein degradation 
mediated by fMet/N-degrons. 
Our 37-kDa reporter, termed P1T2 (“protein-1 containing Thr at position 2”), 
comprised the 11-residue N-terminal sequence MTIAIGTYQEK of the wild-type D2 
protein (D21-11), followed by the sequence 
GSGAWLLPVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRG (a 45-residue 
segment derived from the previously used eK sequence [extension (e) containing lysine (K)] 
[67, 71, 111]), by the 9-residue ha epitope tag (YPYDVPDYA), by the AFLGQ linker [67], 
and by the 267-residue Ura3 protein of the yeast Saccharomyces cerevisiae (Fig. 3A). The 
Ura3 moiety is a frequently employed component of protein reporters [67, 69]. The eK 
segment is another sequence often used in reporters, in part because eK is conformationally 
disordered while lacking degrons in both E. coli and S. cerevisiae [67, 71, 111]. 
P1T2 was expressed from the constitutive PKmR promoter in wild-type, null fmt, and 
null fmt def E.coli strains, followed by extraction of proteins, SDS-PAGE, and 
immunoblotting with anti-ha antibody (Fig. 3A, D). Extracts were adjusted for equal total 
loads using Bradford assay [112] and Coomassie staining of proteins fractionated by SDS-
PAGE (Fig. 3D). The levels of the P1T2 reporter in both fmt and fmt def cells were 
strikingly higher than in congenic wild-type cells, in agreement with the above prediction 
of the fMet/N-degron hypothesis (Fig. 3A, D). 
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The ~70-residue N-terminal segment (D21-11-eK-ha) of the 37 kDa P1T2 reporter 
is a biologically irrelevant mix of different sequences (Fig. 3A). A nascent protein 
exemplified by P1T2, with its disordered N-terminal region, may be less amenable to the 
PDF-mediated deformylation and would be, therefore, a relatively favored target for the 
capture and degradation by the postulated fMet/N-recognin/protease in fMet-containing 
wild-type cells (see Discussion for a more detailed exposition). Conversely, one would 
expect that an up-regulation of such a reporter in formyltransferase-lacking cells may be 
particularly high, in agreement with the observed increase of P1T2 in fmt and fmt def E. coli 
(Fig. 3A, D). 
 
Bypass of Met formylation can equalize the levels of efficacious and poor substrates of 
deformylase  
When the D2 protein, encoded by chloroplast DNA, is expressed in chloroplasts, it 
bears the formylated N-terminal fMet, similarly to nascent bacterial proteins. The fMet of 
D2 is deformylated by two functionally overlapping PDFs in chloroplasts [21]. The Thr 
residue at position 2 of the D2 protein (denoted as D2T2) becomes its N-terminal residue 
once MetAP cleaves off the (previously deformylated) N-terminal Met (Fig. 1B). The N-
terminal sequence fMet-Thr (fMT) of a nascent D2T2 protein is a favorable sequence 
context for the PDF-mediated deformylation of fMet, as had been shown, in particular, in a 
detailed study of substrate preferences of E. coli PDF for amino acid residues downstream 
from fMet [17].  
When Giglione and colleagues [109, 110] carried out pulse-chases to monitor the 
degradation of the wild-type D2T2 protein in chloroplasts, they found this protein to be 
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relatively long-lived under normal conditions. However, D2T2 became short-lived in the 
presence of actinonin, which inhibited the PDF-mediated deformylation of nascent D2T2. 
To address the reason for this effect, Giglione et al. [109, 110] mutated Thr at position 2 of 
D2T2 to either Asp (D) or Glu (E). The resulting mutant proteins D2T2D and D2T2E were 
short-lived in chloroplasts even in the absence of actinonin, i.e., in the absence of PDF 
inhibition [109, 110]. The deformylated N-terminal Met of wild-type D2T2 was expected to 
be cleaved off by MetAP, because Thr is smaller than Val (see Introduction). In contrast, 
N-terminal Met was expected to be retained in the mutant D2T2D and D2T2E proteins, 
inasmuch as both Asp and Glu are larger than Val. Therefore Giglione and colleagues 
interpreted the accelerated degradation of D2T2D and D2T2E (compared to D2T2) in 
chloroplasts as resulting from the retention of their deformylated N-terminal Met, i.e., as 
the consequence of the inability of MetAP to remove deformylated Met from the N-termini 
of D2T2D and D2T2E, in contrast to wild-type D2T2 [110]. 
However, our results (Fig. 3) suggest a different, formyl-based interpretation of the 
above D2 findings [110]. This alternative interpretation ascribes the destruction of the 
mutant D2T2D and D2T2E proteins to a relatively slow PDF-mediated deformylation of N-
terminal fMet if it is followed by either Asp or Glu, in comparison to the at least 10-fold 
faster deformylation of fMet if it is followed, for example, by the Thr residue, which is 
present at position 2 of wild-type D2T2. Thus, we suggest that the correct interpretation of 
the earlier data about the protein D2T2 is the one in which D2T2 can be degraded through its 
fMet/N-degron if deformylation of fMet in D2T2 is inhibited by actinonin. Further, the data 
described below (Fig. 3E, F) suggest that the previously observed rapid destruction of the 
mutant D2T2D and D2T2E proteins [109, 110] is also mediated by their fMet/N-degrons, 
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because the N-terminal fMet-Asp and fMet-Glu sequences of D2T2D and D2T2E are the 
least favorable sequence contexts for the PDF-mediated deformylation of N-terminal fMet, 
as had been shown in a detailed study of the sequence preferences of E. coli PDF [17]. 
The P1T2 protein (D21-11-eK-ha-Ura3) and the otherwise identical P1T2D protein, 
with Asp replacing Thr at position 2, were expressed from the arabinose-inducible Para 
promoter (Fig. 3A, B and Table S2). These reporters were identical, in their 11-residue N-
terminal segments, to the N-terminal sequences of the wild-type D2T2 and mutant D2T2D 
proteins that had been studied in the cited chloroplast-based experiments [109, 110]. Two 
other plasmids expressed the otherwise identical Ub-P1T2 and Ub-P1T2D, i.e., the Ub-fusion 
counterparts of P1T2 and P1T2D (Fig. 3C and Table S2). 
Ub is not recognized as a degron in wild-type E. coli. However, a Ub fusion can be 
cotranslationally cleaved in E. coli if they express a deubiquitylating (DUB) enzyme such 
as Ubp1 of S. cerevisiae [75, 113, 114]. Placing the Ub moiety in front of two reporters and 
expressing the resulting Ub fusions in Ubp1-containing E. coli allowed the production of 
P1T2 and P1T2D through the site-specific removal, by Ubp1, of the N-terminal Ub moiety. 
(This version of the Ub fusion technique was developed in our studies of the E. coli N-end 
rule pathway [75, 113, 114].) The difference between two modes of reporter expression, the 
direct one and the Ub fusion-mediated one, is the transient presence of the formylated fMet 
residue at the N-termini of directly produced P1T2 and P1T2D vs. the presence of 
unformylated N-terminal Met in the otherwise identical P1T2 and P1T2D that had been 
generated from Ub-P1T2 and Ub-P1T2D through the removal of their Ub moiety (Fig. 3C). It 
should be noted that although N-terminal fMet was present at the N-terminus of nascent Ub 
upon the expression of Ub-P1T2 and U-P1T2D in E. coli, the rapid folding of the emerging 
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Ub moiety would be expected to facilitate deformylation of its N-terminal fMet, thereby 
abrogating its fMet/N-degron (Fig. 1D). 
Equal total protein loads were controlled as described above for P1T2 in wild-type 
and fmt cells (Fig. 3D). Extracts from wild-type E. coli containing the directly expressed 
P1T2 and P1T2D reporters were fractionated by SDS-PAGE, followed by immunoblotting 
with anti-ha antibody (Fig. 3E, F). Whereas the band of P1T2 could be detected in cells 
growing in the presence of arabinose, the level of the otherwise identical P1T2D, containing 
Asp at position 2 (this is an unfavorable sequence context for fMet deformylation [17]) was 
either too low for detection in one experiment (Fig. 3F, lanes 1-4) or was detectable but 
considerably lower than the level of P1T2 in another, independent experiment (Fig. 3E, 
lanes 1-4).  
In contrast, when the same two reporters, P1T2 and P1T2D, were expressed as Ub 
fusions in E. coli that also expressed the yeast Ubp1 DUB enzyme, two changes were 
observed. First, the yields of both reporters were greatly increased. Second, their steady-
state levels, instead of being strongly different upon reporters’ direct expression, became 
equal (Fig. 3C, E, F). Expression of the same Ub fusions in E. coli lacking the Ubp1 DUB 
yielded equal levels of the larger, unprocessed Ub-P1T2 and Ub-P1T2D fusions (Fig. 3F, 
lanes 9-12). 
These findings (Fig. 3B, C, E, F), together with the data about P1T2 in wild-type vs. 
fmt E. coli (Figs. 3A, D), suggested that the N-terminal fMet residue of both nascent and 
just completed, newly formed proteins can participate in two alternative transitions: the 
PDF-mediated deformylation of N-terminal fMet vs. its capture by the postulated 
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fMet/N-recognin/protease and the ensuing processive degradation of a targeted protein 
(Fig. 1C-E and Discussion). 
 
Formylation-dependent selective destabilization of a reporter protein 
In these 35S-pulse-chase assays, our reporters were derivatives of a natural cytosolic 
E. coli protein, the 164-residue PpiB peptidyl-prolyl cis-trans isomerase [115]. One feature 
of these assays (Fig. 4) was a “built-in” reference protein. fMVTF, the N-terminal sequence 
of PpiB, is a motif favored by the E. coli PDF deformylase [17]. This sequence is indicated 
by the superscript on the left side of the term PpiB୵୲୑୚୘୊ f, which denotes the C-terminally 
flag-tagged wild-type PpiB, a reference protein. It was coexpressed with one of two 
otherwise identical reporters, termed, respectively, MYFYPpiBf-Ub and MDDDPpiBf-Ub (Fig. 
4). The reference protein PpiB୵୲୑୚୘୊ f and the reporter MYFYPpiBf-Ub were coexpressed from 
two identical, arabinose-inducible, tandemly arranged Para promoters (Fig. 4A, B). An 
otherwise identical plasmid coexpressed the reference PpiB୵୲୑୚୘୊ f and the reporter 
MDDDPpiBf-Ub (Fig. 4C, D and Table S2).  
The two reporters, MYFYPpiBf-Ub and MDDDPpiBf-Ub, differed from the reference 
PpiB୵୲୑୚୘୊ f at two places: by the sequence of three residues following N-terminal Met and 
by the presence of the ~8 kDa Ub moiety C-terminally to the PpiBf moiety (Fig. 4A, C). 
The Ub moiety was linked, C-terminally, to the PpiB moiety solely for making it easy to 
distinguish, by SDS-PAGE, the resulting reporters MYFYPpiBf-Ub and MDDDPpiBf-Ub from 
the reference PpiB୵୲୑୚୘୊ f (Fig. 4).  
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Three residues, Val-Thr-Phe, which follow N-terminal Met in wild-type PpiB, 
were replaced, in MYFYPpiBf-Ub and in MDDDPpiBf-Ub, by the sequences Tyr-Phe-Tyr 
(YFY) and Asp-Asp-Asp (DDD), respectively (Fig. 4). MYFYPpiBf-Ub was our “rapidly 
deformylatable” reporter (also called reporter-1), since N-terminal sequences of the kind 
exemplified by the sequence fMYFY are kinetically favorable contexts for the 
PDF-mediated deformylation of N-terminal fMet (Fig. 4A) [17]. The N-terminal sequence 
fMVTF, of the reference PpiB୵୲୑୚୘୊ f, is also a favorable motif for the PDF-mediated 
deformylation of N-terminal fMet [17]. 
The encoded N-terminal sequence of MDDDPpiBf-Ub (reporter-2) was Met-Asp-Asp-
Asp (MDDD) (Fig. 4C). MDDDPpiBf-Ub was our “slowly deformylatable” reporter, because 
the N-terminal sequence fMDDD has been shown to be among the most unfavorable 
contexts for the PDB-mediated deformylation of N-terminal fMet [17]. Deformylation, by 
purified E. coli PDF, of synthetic peptides bearing N-terminal fMet was at least 10-fold 
faster for most favorable fMet sequence contexts, in comparison to least unfavorable ones 
[17]. These sequence motifs were exemplified, in our reporters, by fMYFY and fMVTF 
(favorable contexts) vs. fMDDD (unfavorable context) (Fig. 4A, C). 
If fMet/N-degrons exist (in other words, if the postulated fMet/N-recognin/protease 
exists), the relatively slowly deformylated reporter-2 and the relatively rapidly 
deformylated reporter-1 would be vulnerable both to the PDF-mediated deformylation of 
their N-terminal fMet (a step that abrogates fMet/N-degrons) and to the alternative, 
competing event of capture and processive degradation of a reporter protein through its 
fMet/N-degron. In the latter outcome, the postulated fMet/N-recognin/protease succeeds in 
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binding to N-terminal fMet before its deformylation by PDF. Either one of these 
mutually exclusive steps would take place while the polypeptide chain of a nascent reporter 
continues to emerge from the ribosomal tunnel at the rate of 10-20 residues/sec. 
Given this disposition, one key prediction of the fMet/N-degron hypothesis is as 
follows: if the N-terminal fMet residue of one nascent protein (reporter-2) is deformylated 
significantly slower than fMet of another (nearly identical) nascent protein (reporter-1) 
(Fig. 4A, C), the molecules of reporter-2 would be targeted for destruction more often 
through its (more frequently retained) fMet/N-degron, resulting in a higher rate of 
degradation of reporter-2.  
Because these events are expected to involve largely nascent, still growing 
polypeptide chains, the second prediction is that a difference in degradation rates between 
reporter-1 and reporter-2 in wild-type E. coli may be largely confined to previously 
glimpsed proteolytic processes referred to as the “time-zero”, “before-chase” proteolysis 
[67-69, 71, 97, 116-118]. These effects result from the processive cotranslational 
degradation, in contrast to posttranslational degradation. While the posttranslational 
degradation of a protein is measured during a chase, the extent of cotranslational 
degradation of the same protein is determined by comparing time-zero (before chase) levels 
of this protein and an otherwise identical protein that lacks (or nearly lacks) the relevant 
degron [67-69, 71, 97, 116-118]. Given the second prediction above, the presence, in our 
assays, of the “built-in” reference protein PpiB୵୲୑୚୘୊ f (Fig. 4) was particularly important, 
because a reference greatly increases the accuracy of quantifying both cotranslational and 
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posttranslational degradation, with the cotranslational mode revealing itself through 
time-zero, before-chase effects. 
The third and equally critical prediction of the fMet/N-degron hypothesis: if a faster 
degradation of the more slowly deformylated reporter-2 is actually observed in wild-type 
cells (possibly as a time-zero, before-chase effect), this effect should vanish if 35S-pulse-
chases are performed in fmt cells, which lack formyltransferase and therefore lack fMet/N-
degrons. 
Experiments designed as described above were carried out. The results were in 
agreement with all three predictions of the fMet/N-degron hypothesis (Fig. 4). 
In the first set of 35S-pulse-chases, wild-type E. coli and its fmt mutant (lacking Met 
formylation) were transformed with pKP458, which expressed, from two identical Para 
promoters, the rapidly deformylatable PpiB୵୲୑୚୘୊ f reference and the also rapidly 
deformylatable MYFYPpiBf-Ub reporter-1 (Fig. 4A, B and Table S2). Arabinose was added 
to induce expression of the two proteins, followed by 1-min pulse with 
35S-methionine/cysteine at 37°C, chases for 1, 3, 7, 15 and 30 min, preparation of cell 
extracts, immunoprecipitation of PpiB୵୲୑୚୘୊ f and MYFYPpiBf-Ub with anti-flag antibody, 
fractionation of precipitated proteins by SDS-PAGE, and autoradiography. The data were 
quantified by plotting, on a semi-logarithmic scale, the ratios of 35S in the band of the 
MYFYPpiBf-Ub reporter-1 to 35S in the band of the reference PpiB୵୲୑୚୘୊ f (Fig. 4A, B, E). 
PpiB୵୲୑୚୘୊ f and MYFYPpiBf-Ub were relatively stable over the 30-min chase in wild-
type and fmt E. coli. In addition, no significant differences in 35S ratios of MYFYPpiBf-Ub to 
PpiB୵୲୑୚୘୊ f at the time-zero (before chase) point were observed between wild-type and fmt 
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cells (Fig. 4E; curves 1 and 2). That was expected, given the approximately equal rates of 
the PDF-mediated deformylation of the reference and reporter-1, as described above. 
In the second set of 35S-pulse-chases, wild-type and fmt E. coli were transformed 
with pKP459, which expressed, from the two Para promoters, the rapidly deformylatable 
PpiB୵୲୑୚୘୊ f and the relatively slowly deformylatable MDDDPpiBf-Ub reporter-2 (Fig. 4C, D 
and Table S2). This comparison revealed a strikingly high ~8-fold difference between the 
rates of time-zero, before-chase degradation of the rapidly deformylatable MYFYPpiBf-Ub 
reporter-1 and the relatively slowly deformylatable MDDDPpiBf-Ub reporter-2, indicating a 
much higher rate of the early, presumably cotranslational degradation of the (relatively) 
slowly deformylated MDDDPpiBf-Ub in wild-type cells (Fig. 4E; curves 2 and 4). Crucially, 
the bulk of this effect was abrogated when the otherwise identical 35S-pulse-chases were 
performed in fmt cells, which did not formylate N-terminal Met and therefore could not 
create fMet/N-degrons (Fig. 4E; curves 1 and 3).  
While the degradation of the MDDDPpiBf-Ub reporter-2 in wild-type cells was 
largely of the time-zero, before-chase kind, this reporter was also destroyed, relatively 
slowly, during chases in both wild-type and fmt cells (Fig. 4C-E; curves 3 and 4). In 
contrast, little posttranslational degradation was observed with the MYFYPpiBf-Ub reporter 
(differing from MDDDPpiBf-Ub by three residues after N-terminal Met) in either wild-type or 
fmt cells (Fig. 4A, B, E). A parsimonious interpretation of the slow posttranslational 
degradation of MDDDPpiBf-Ub is that the sequence of three Asp residues after N-terminal 
Met may have created a weak, largely posttranslational and formylation-unrelated degron. 
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The design of these assays, i.e., their built-in reference protein as well as two 
identical transcriptional promoters expressing a reference and a reporter in wild-type vs. 
fmt cells, controlled for variables other than protein degradation (Fig. 4A, C). The ~8-fold 
difference in the time-zero, before-chase levels of the rapidly deformylated reporter-1 and 
the relatively slowly deformylated reporter-2 in wild-type cells, and the dependence of this 
effect on the presence of formyltransferase (Fig. 4E) seem to allow only one plausible and 
parsimonious interpretation. Specifically, we posit that this difference and its dependence 
on Nt-formylation indicated the presence, in our reporters, of PDF-vulnerable fMet/N-
degrons (Figs. 1C-E and 4). 
 
Discussion 
Key results of the present study are the evidence that rapidly and slowly 
deformylated protein reporters are destroyed at different rates in wild-type E. coli, and that 
this effect is abrogated in formylation-lacking fmt mutants. These and related findings 
strongly suggest that the formylated N-terminal fMet residue can act as an N-degron, 
termed fMet/N-degron, of a novel bacterial N-end rule pathway, termed the fMet/N-end 
rule pathway (Figs. 1-4). 
 
Incomplete deformylation of nascent bacterial proteins in vivo  
N-terminal fMet of nascent polypeptides can be incompletely deformylated by PDF 
in vivo [60, 119]. The incomplete deformylation is particularly pronounced with DNA-
encoded, ribosome-generated small natural peptides [120]. For example, the bulk of 
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secreted 7-residue microcin-C peptide is not deformylated in vivo [120], although this 
peptide’s second residue, in the N-terminal sequence fMet-Arg, is one of position-2 
residues that are optimal for deformylation of fMet by PDF [17].  
The molar concentration of PDF in E. coli is 2-3 μM, an order of magnitude below 
that of the ribosomes, ~30 μM [7, 23, 37]. Consequently, an efficacious deformylation of 
nascent proteins requires that molecules of PDF “hop” among the PDF-binding sites of 
different ribosomes. Given the resulting stochasticity of deformylation, given low steady-
state levels of PDF in the bulk solvent (since most PDF molecules are ribosome-bound), 
and given a significant dependence of the rate of deformylation by PDF on fMet-proximal 
sequence contexts [17, 18], one should expect an incomplete deformylation of bacterial 
proteins to be a frequent occurrence [60, 119]. For example, a 2-D electrophoretic study of 
abundant Bacillus subtilis proteins indicated that some of them retained, at steady-state, a 
small but significant fraction of their initial (formylated) N-terminal fMet [121]. 
Analyses, using 2-D electrophoresis, of the in vivo inhibition of fMet deformylation 
by the PDF-specific inhibitor LBM-415 in Staphylococcus aureus and Streptococcus 
pneumoniae demonstrated the accumulation of formylated (non-deformylated) counterparts 
of normally deformylated proteins [122]. Interestingly, while a subset of proteins in LBM-
415-treated bacterial cells exhibited a telltale double-spot appearance on 2-D gels (a 
formylated plus deformylated species), many other proteins remained as single spots, 
without formylated counterparts [122]. This finding, remarked upon but not explained by 
the authors [122], might signify the selective degradation of some formylated proteins 
through fMet/N-degrons suggested by the results of our study (Figs. 1-4). In this 
interpretation of the data in ref. [122], those proteins that accumulate, in the presence of 
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PDF inhibitor, as formylated (non-deformylated) species, might be partially protected 
from degradation owing to a steric shielding (sequestration) of their fMet/N-degrons, either 
through intramolecular protein folding or through the formation of “protective” oligomeric 
complexes with cognate protein ligands. The latter mechanism would be analogous to the 
previously discovered shielding-mediated conditionality of natural eukaryotic 
Ac/N-degrons [68]. 
 
Working model of fMet/N-degrons  
The idea of fMet/N-degrons was sketched in ref. [67]. It is now described in detail 
(Fig. 1C-E) vis-á-vis the data (Figs. 2-4). 
First, we presumed that a distinct fMet/N-recognin/protease (envisioned as a 
transient complex of both) can recognize, in a competition with PDF, the N-terminal fMet 
moiety of a nascent protein and thereby initiate a processive destruction of this protein 
either cotranslationally or posttranslationally. The latter distinction is based on whether the 
protein’s N-terminal fMet is captured by the fMet/N-recognin/protease before or after the 
protein’s nascent polypeptide chain is released from the last tRNA molecule at the 
ribosome’s peptidyltransferase site. Cotranslational protein degradation is defined as the 
processive degradation of a nascent, growing polypeptide that exists, at the time of 
proteolytic attack, as a ribosome-associated peptidyl-tRNA.  
A proteolytic pathway that targets a specific degron in a protein and converts the 
bulk of it to short peptides must be highly processive. A nonprocessive protease would tend 
to release an initially captured protein and thereby would lose it for good if a protein’s 
segment containing the degron had already been destroyed. The postulated bacterial 
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fMet/N-recognin/protease is envisioned to be a processive proteasome-like protease, 
possibly one of the known ones, such as, for example, FtsH, Lon, or a ClpP-containing 
protease [123] (see also Concluding Remarks). One protease of the latter class, ClpXP, is 
unlikely to be involved, because its in vitro activity toward a test protein was shown to be 
independent of the presence or absence of Nt-formylation [22]. 
The degradation of an fMet-bearing nascent protein, i.e., of a ribosome-bound 
peptidyl-tRNA, would proceed to completion once it begins, after the recognition of 
protein’s N-terminal fMet. During this (postulated) degradation, the fMet/N-
recognin/protease, having captured the protein’s N-terminal fMet, would remain associated 
with the translating ribosome. The emerging chain of a nascent protein would continue to 
be delivered into the protease’s chamber and destroyed to short peptides until the natural 
(i.e., not premature) chain termination event at the ribosome’s peptidyl-transferase site. An 
alternative possibility is that the initiation of cotranslational degradation of a ribosome-
associated peptidyl-tRNA would lead, through allosteric effects, to a premature termination 
of translation. 
Second, the fMet/N-recognin/protease or at least its fMet/N-recognin part was 
presumed to have a non-zero affinity for the ribosomes, forming a “cloud” of fMet/N-
recognin/protease molecules (or fMet/N-recognin alone) “hugging” the ribosomes. The 
analogous cloud of ribosome-hopping PDF molecules [23] would partially overlap with the 
(presumed) cloud of fMet/N-recognin/protease molecules. One version of this model 
envisions a “tighter cloud” of ribosome-hopping PDF molecules, i.e., a smaller time-
averaged distance between them and the ribosomes, in comparison to a “looser cloud” of 
fMet/N-recognin/protease molecules, reflecting their (presumed) lower affinity for the 
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ribosomes. In such a setting, which was partly characterized for PDF [23] and is 
postulated here for the fMet/N-recognin/protease (or its fMet/N-recognin part), a molecule 
of ribosome-bound PDF would have a stochastically better “shot” at binding to and 
deformylating N-terminal fMet of an emerging nascent protein. The term “looser cloud” 
implies a larger time-averaged distance of the fMet/N-recognin/protease from the tunnel’s 
exit, in comparison to PDF. Whether the “cloud” model is relevant to a postulated fMet/N-
recognin rather than to a “downstream” protease remains to be seen, particularly if the 
protease in question is the inner membrane-embedded FtsH protease (see Concluding 
Remarks). 
In this working model of fMet/N-degrons, some non-wild-type N-terminal 
sequences, once they emerge from the ribosomal tunnel, would either not collapse rapidly 
enough, or would collapse into globules that impede deformylation of N-terminal fMet by 
PDF. In the latter case, a collapse may prevent, at least in part, an exposure of the roughly 
10-residue N-terminal region (including its fMet) on the globule’s surface. As a result, the 
ribosome-bound PDF would often fail to deformylate fMet, given the narrow 
kinetic/stochastic window of opportunity that PDF is allowed to have (Fig. 1C-E). As to the 
former case, the radii of gyration of folded polypeptides with lengths of up to 100 residues 
are 1.0-1.2 nm, whereas the radii of gyration of unfolded polypeptides increase from ~1.0 
to ~3.0 nm as their length increases from 8 to 100 residues [124]. In such a setting, the N-
terminal fMet residue of a (largely) unfolded polypeptide may be stochastically and 
partially buried in a fluctuating, partially folded conformation, thereby impeding the 
capture and deformylation of fMet by the ribosome-bound PDF (Fig. 1C-E).  
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Results of a study based on the ribosome profiling technique suggested that the 
PDF-mediated deformylation of nascent bacterial proteins takes place, in the main, before 
they become significantly larger than ~100 residues [28]. Thus, the postulated targeting of 
a nascent Nt-formylated protein for processive degradation through its fMet/N-degron (Fig. 
1C-E) may be “decided upon” largely on the basis of protein’s first 100 or so residues. In 
other words, significantly more distal regions of a protein may often not be involved.  
Given this disposition, we suggest that ~100-residue N-terminal regions of bacterial 
proteins evolve under a selection pressure that tends to maximize their ability to collapse 
into a “molten globule” [125] in which roughly 10 N-terminal residues, including 
N-terminal fMet, tend to be extruded from the globule and exposed to solvent. 
Consequently, PDF would be able to deformylate a nascent protein before the N-terminal 
fMet residue would move too far away from the ribosome-bound PDF, owing to the 
ongoing elongation of the protein’s polypeptide chain (Fig. 1C, D). Entries in Protein Data 
Bank (PDB; http://www.rcsb.org/pdb/home/home.do) exhibit a tendency for N-terminal 
regions to be weakly ordered in crystal structures. Moreover, such regions are often absent 
altogether in published structures, having been removed from the proteins’ natural N-
termini to allow crystallization. For example, the first high-resolution structures of 
“soluble” eukaryotic proteins with intact natural N-terminal regions (usually in complexes 
with their cognate protein ligands) have been determined only recently [126-128]. 
Third, the kinetic advantage of PDF in targeting the N-terminal fMet residue would 
be transient, because a stochastic failure of PDF to capture and deformylate fMet of a 
nascent protein would soon (within seconds) position that fMet outside the physical reach 
of a ribosome-bound PDF molecule, owing to the ongoing elongation of the protein’s 
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polypeptide chain. It would be, then, the stochastic and also transient turn of the less 
tightly ribosome-bound fMet/N-recognin/protease or its fMet/N-recognin part (resulting in 
its larger time-averaged distance from the ribosomes) to capture the N-terminal fMet 
residue, whose distance from the tunnel’s exit may continue to increase as the nascent 
polypeptide keeps emerging from the ribosome. 
Fourth, the main (but not necessarily the sole) function of postulated fMet/N-
degrons (Fig. 1E) is envisioned to be the quality control of nascent bacterial proteins and 
just released, newly formed proteins. This role of bacterial fMet/N-degrons would be 
similar to the previously identified quality-control function of eukaryotic Ac/N-degrons 
[67-70]. The naturally high (~10-3 per residue) frequency of amino acid misincorporation 
during protein synthesis can be further increased by antibiotics that elevate the ribosome’s 
error rate. Such antibiotics are endemic in natural bacterial habitats [7, 51]. On the 
assumption that the error rate is approximately uniform along the sequence of a translated 
polypeptide, a significant fraction of N-terminal regions of nascent proteins would be 
mutant vis-á-vis their wild-type DNA-encoded sequences even in the absence of stress. The 
frequency of abnormal (mistranslated) sequences would be further elevated in the presence 
of fidelity-decreasing antibiotics or other stresses. 
Fifth, some molecules of just completed, newly formed proteins would 
stochastically and at least transiently bypass the targeting by both PDF and the postulated 
fMet/N-recognin/protease. The non-ablated fMet/N-degrons of such proteins are 
envisioned to be often rapidly repressed through their steric shielding (sequestration), 
owing to interactions of newly formed proteins with their cognate ligands, which can be 
other proteins, RNA or DNA. In contrast, a nascent or a newly formed Nt-formylated 
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protein that cannot form such “protective” complexes efficaciously enough or cannot 
form them at all (owing, for example, to its misfolding) would remain vulnerable to either 
the destruction by the postulated fMet/N-recognin/protease or to the PDF-mediated 
deformylation of N-terminal fMet, a step that abrogates the protein’s fMet/N-degron. This 
model presumes a low level of PDF away from the ribosomes, in agreement with 
experimental evidence [23]. In contrast, the postulated fMet/N-recognin/protease (or its 
fMet/N-recognin part), while also ribosome-associated, is presumed to be present at 
significant levels in the bulk solvent as well. 
Studies by Green and colleagues employed defined in vitro translation systems and 
showed that a bacterial (but apparently not eukaryotic) ribosome can sense a 
misincorporation of a non-cognate residue during protein synthesis and react through a 
further decreased fidelity of translation downstream from the incorrect amino acid residue 
[129, 130]. This error-induction response increases the probability of premature translation 
termination and the release of a mistranslated nascent polypeptide [129]. The extent of 
Green’s effect remains to be determined in vivo. If the frequency of nascent polypeptides 
that are prematurely terminated in living bacteria owing to this effect is as high as it was 
observed to be in vitro [129], one would expect a significant frequency of Nt-formylated, 
mistranslated and prematurely terminated proteins that emerge from the ribosomal tunnel 
while bearing fMet/N-degrons. Owing to misincorporation events that led to their 
premature release, such (incomplete) proteins would often fold either abnormally or not at 
all. These properties may render them less susceptible to deformylation. 
The temporal and geometric aspects of N-terminal fMet vis-á-vis other participants 
in this kinetic drama would vary from one nascent protein to another, at least in part 
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because the rate of PDF-mediated deformylation of fMet in a nascent protein depends on 
the identities of residues at position 2 and beyond [17]. In sum, the folding (or misfolding) 
of a growing nascent protein, and the propensity (or its absence) of N-terminal fMet to 
remain sterically accessible to PDF on the surface of a nascent protein globule would affect 
the outcomes of competition between the ribosome-associated PDF and the postulated 
fMet/N-recognin/protease. This glimpse of possible mechanics is an illustration of 
complexities that remain to be understood vis-á-vis the concept of fMet/N-degrons (Fig. 
1C-E). 
 
Concluding remarks  
The fMet/N-degron hypothesis was proposed in 2010 [67]. The difficulty in 
viewing (let alone proving) the N-terminal fMet residue as a degradation signal stems from 
the transiency of the formyl group of N-terminal fMet in a majority of nascent bacterial 
proteins. 
The rate of chain elongation by bacterial ribosomes in vivo at 37°C is 10-20 
residues/sec, i.e., it is up to an order of magnitude higher than estimated rates of chain 
elongation by the cytosolic ribosomes in eukaryotes [49-52]. Faster emergence of nascent 
proteins from bacterial ribosomes may have precluded the adoption, during bacterial 
evolution, of cotranslationally (as distinguished from pretranslationally) created N-degrons, 
such as, for example, Ac/N-degrons in eukaryotes (Fig. S1B). Notably, the Nt-acetylation 
of many eukaryotic proteins is known to be incomplete [103], i.e., the cotranslational 
generation of Ac/N-degrons is often not efficacious enough even at relatively low rates of 
chain elongation in eukaryotes. This fact is consistent with the view that the observed 
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pervasiveness of the pretranslational formylation of N-terminal Met (all examined wild-
type bacteria contain fMet) resulted from selection pressures to maximize the extent of Met 
formylation vis-á-vis high rates of polypeptide chain elongation. 
Competition among bacteria and other microorganisms often involves antibiotics 
that increase the frequency of translational errors in susceptible strains. One function of 
fMet/N-degrons is envisioned to be the preferential degradation of misfolded nascent 
proteins. Thus, stresses caused by perturbed translation, including antibiotics-mediated 
conflicts in the microbial world, may be a source of selection pressures that retained the 
apparatus of bacterial fMet/N-degrons. 
Now that the first evidence for fMet/N-degrons has been produced (Figs. 1-4), the 
next essential step is to identify the postulated, possibly two-component 
fMet/N-recognin/protease. A recent study by Bittner et al. [131] described the N-terminal 
degradation signal of YfgM, an inner membrane-embedded E. coli protein. Analyses by 
Bittner et al. [131] did not invoke either an fMet/N-degron or the formylation of N-terminal 
Met. However, specific properties of the cytosol-facing N-terminal degron of YfgM [131] 
suggested, to us, that this degradation signal may be an fMet/N-degron. If so, the inner 
membrane-embedded, ATP-dependent FtsH protease would be the one that targets the N-
terminal fMet residue (either directly or through an unknown fMet/N-recognin), because 
Bittner al. [131] identified FtsH as the protease that destroys YfgM. Remarkably, our 
recent studies showed that the degron of YfgM is, in fact, an fMet/N-degron, thereby 
identifying FtsH as the relevant protease (T.T.M.V., K.P. and A.V., unpublished data). 
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Materials and Methods 
 
Miscellaneous reagents 
Anti-flag M2 Magnetic Beads (M8823), anti-flag M2 antibody, and anti-ha 
antibody were from Sigma-Aldrich. Complete EDTA-free Protease Inhibitor Cocktail 
Tablets were from Roche. Express [35S] Protein Labeling Mix (1.175 Ci/mmol) was from 
Perkin-Elmer. Methionine/cysteine-free synthetic complete ("Hopkins") supplement 
mixture (SC) was from Sunrise Science Products. Actinonin was from Enzo Life Sciences. 
 
Bacterial strains and mutagenesis 
E. coli strains (Table S1) were grown at 37°C on Luria-Bertani (LB) medium. 
When used for selection, antibiotics were added to the following final concentrations: 
kanamycin (Km): 50 μg/ml; ampicillin (Amp): 100 μg/ml. Null fmt and def-fmt E. coli 
mutants (strains KPS73-KPS76) (Table S1) were constructed using a gene disruption 
strategy [132]. The resulting E. coli mutants were grown in LB under selective conditions. 
The desired deletions were verified by polymerase chain reaction (PCR), followed by 
sequencing of PCR-amplified, purified DNA fragments. 
 
Construction of plasmids 
E. coli DH5α (Invitrogen) was used for cloning and maintaining plasmids. Phusion 
High-Fidelity DNA polymerase (New England Biolabs) was used for PCR. Specific DNA 
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constructs were generated using standard techniques [112] and verified by DNA 
sequencing. 
The plasmids containing one or two Para promoters were derived from the pBADET 
vector, a gift from Dr. V. Ksenzenko (Institute of Protein Research, Pushchino, Russia). 
The plasmids pKP249 and pKP250, which expressed P1T2X (P1T2X-eK-ha-Ura3) fusion 
proteins (X=Thr or Asp) from the Para promoter, were constructed by subcloning a 
NdeI/HindIII-digested DNA fragment (produced by PCR from pCH178; Table S2) into the 
NdeI/HindIII-cut plasmid pBADET (Table S2). (The DNA fragment from pCH178 that 
encoded eK-ha-Ura3 was extended, by PCR, to yield fragments encoding either P1T2-eK-ha-
Ura3 or P1T2D-eK-ha-Ura3.) To construct pKP251 and pKP252, which expressed Ub-P1T2X 
fusion proteins from the Para promoter, a DNA fragment containing the ORF of Ub was 
PCR-amplified (using the pCH178 plasmid as a template), digested with NdeI/BspEI and 
subcloned into NdeI/BspEI-cut pKP249 and pKP250 (Table S2). To construct pKP257 and 
pKP258, which expressed P1T2X proteins (P1T2X-eK-ha-Ura3) (X=Thr or Asp) from the 
PKmR promoter, NdeI/HindIII-digested fragments, produced by PCR from pKP249 and 
pKP250, were subcloned into NdeI/HindIII-cut pACYC177 (Table S2). The plasmids 
pKP286 and pKP287, which expressed MXXXPpiB-His8-flag (MXXXPpiBf) proteins 
(XXX=Val-Thr-Phe or Asp-Thr-Phe), were constructed by subcloning a NdeI/XbaI-
digested DNA fragment (encoding PpiB and produced by PCR from MG1655 E. coli 
genomic DNA) into NdeI/XbaI-cut pBADET (Table S2). The plasmids pKP458 and 
pKP459, each of which expressed two PpiB-derived proteins from two identical Para 
promoters (Fig. 4) were constructed as follows. DNA fragment containing the Para 
promoter was PCR-amplified from pBADET (Table S2). DNA fragment encoding 
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MXXXppiB-His8-flag-Ub (MXXXPpiBf-Ub) (XXX=Tyr-Phe-Tyr or Asp-Asp-Asp) was 
PCR-amplified from pKP335 (Table S2). The resulting DNA fragments were linked 
together using PCR, digested with AfeI/NsiI and thereafter subcloned into AfeI/NsiI-cut 
pKP286 (Table S2). Additional cloning details are available on request. 
 
Immunoblotting assays 
Methods for data in Fig. 3D: wild-type and mutant E. coli (CAG12184, KPS73 and 
KPS74; Table S1) carrying pKP257 (Table S2) were grown at 37°C overnight in Growth 
Medium (GM) (M9 medium (33.9 mg/ml Na2HPO4, 15 mg/ml KH2PO4, 5 mg/ml NH4Cl, 
2.5 mg/ml NaCl, pH 7.0), 0.5% glycerol, 0.2% glucose, 40 μg/ml Met, 40 μg/ml Cys, 
methionine/cysteine-free synthetic complete (SC) mixture (Sunrise Science Products) 
supplemented with ampicillin (Amp; 50 µg/ml)). Cultures were diluted 1:100 in 30 ml of 
GM medium and incubated on a shaker at 37°C until A600 of ~0.5. The resulting cultures 
(10 ml) were centrifuged at 5,000g for 5 min at 4°C, washed three times with 1-ml samples 
of ice-cold phosphate-buffered saline (PBS) and thereafter lysed in 0.1 ml volumes of 1% 
SDS. The resulting extracts were clarified by centrifugation at 14,000g for 5 min at 4°C, 
and protein concentration in the supernatants were determined using Pierce BCA Protein 
Assay (Fisher Scientific). Samples were mixed with equal volume of 2x SDS-sample 
buffer and heated at 95°C for 10 min. 25 μg of total protein in the resulting samples were 
subjected to SDS-4-12% NuPAGE (Invitrogen), followed by immunoblotting, using 
standard procedures [67, 68] with a monoclonal anti-ha antibody (1:2,000) (Sigma-
Aldrich), with detection using ECL Plus (GE Healthcare). 
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Methods for data in Fig. 3E, F: wild-type E. coli CAG12184 (Table S1) carrying 
pKP249-252, and pJT184 (Table S2) were grown at 37°C overnight in GM medium as 
described above. Cultures were diluted 1:100 in 30 ml of GM medium and incubated at 
37°C until A600 of ~0.35. Cells were pelleted by centrifugation 5,000g for 5 min at room 
temperature (RT), washed with 1 ml of Induction Medium-Ara-0.25 (IM-Ara-0.25) (M9 
medium (pH 7.0), 0.5% glycerol, 0.25% arabinose, 40 μg/ml Met, 40 μg/ml Cys, 
methionine/cysteine-free synthetic complete (SC) mixture) and resuspended in 30 ml of 
IM-Ara-0.25 medium. After 90 min of incubation at 37°C, the resulting cultures (10 ml) 
were centrifuged at 5,000g for 5 min at 4°C, washed three times with 1-ml samples of ice-
cold PBS and thereafter processed for lysis, SDS-PAGE, and immunoblotting with anti-ha 
antibody as described above. 
 
Pulse-chase assays without immunoprecipitation 
Methods for data in Fig. 2A: wild-type E. coli CAG12184 cells (Table S1) were 
grown in LB medium at 37°C overnight. 0.75 ml of overnight culture in LB was washed 
with 1 ml of GM medium, resuspended in 30 ml of GM, and was grown until A600 of 
~0.35. Cells were pelleted by centrifugation at 5,000g for 5 min at RT, washed with 1 ml of 
pre-warmed IM-Ara-0.25 medium and resuspended in 30 ml of pre-warmed IM-Ara-0.25. 
After 90 min of incubation on a shaker at 37°C in IM-Ara-0.25, 15 ml of the culture were 
centrifuged at 5,000g for 5 min at RT, and washed 2 times with 1-ml samples of pre-
warmed Pulse Medium-025 (PM-Ara-0.25), which differed from the IM-Ara-0.25 medium 
by lacking Met and Cys. Cell pellet was resuspended in 1 ml of PM-Ara-0.25 and divided 
into 4 equal samples, which were incubated for 10 min at 37°C with agitation. Actinonin 
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was added (to the final concentrations indicated in panels of Fig. 2A, B) at the beginning 
of 10-min incubations and was kept at the same concentrations throughout pulse-chases. 
Thereafter the cultures were labeled with 15 µl of Express [35S] Protein Labeling Mix 
(1.175 Ci/mmol, Perkin Elmer) for 1 min at 37°C, followed by centrifugation at 14,000g 
for 30 sec at RT. Each supernatant was added to 0.3 ml of Chase Medium (CM) (M9 
medium (pH 7.0), 0.5% glycerol, 0.5% glucose, 0.5 mg/ml Met, 0.5 mg/ml Cys, 0.2 mg/ml 
chloramphenicol, methionine/cysteine-free synthetic complete (SC) mixture), followed by 
a chase, also at 37°C. Samples (0.1 ml) were withdrawn at indicated times during chase, 
followed by immediate freezing in liquid nitrogen. For further analyses, one volume of 
2x-SDS-PAGE sample buffer was added to a frozen sample, followed by heating at 95°C 
for 10 min, brief vortexing and centrifugation at 12,000g for 5 min. 5 µl of each “time-
zero” sample were spotted on Whatman 3MM filters, immersed in ice-cold 10% 
CCl3COOH for 5 min, boiled in 10 % CCl3COOH for 10 min, rinsed (for 15 sec) 3 times in 
5% CCl3COOH, washed (for 5 min) 2 times with 5% CCl3COOH, rinsed 3 times with 95% 
ethanol, and air-dried, followed by measurements of 35S using Safety-Solve scintillation 
cocktail and scintillation spectrometer. 20,000 35S cpm of each time-zero sample (Fig. 2B), 
and equal volumes of samples at later time points were subjected to SDS- 4-12% PAGE, 
followed by autoradiography. 
Methods for data in Fig. 2B: wild-type (CAG12184) and fmt (KPS73) E. coli 
(Table S1) were grown in LB medium at 37°C overnight. Cultures were diluted 1:200 in 
the GM medium and incubated at 37°C until A600 of ~0.5. The resulting culture (7 ml) was 
centrifuged at 5000g for 5 min at room temperature, washed three times with 1-ml samples 
of pre-warmed PM-Ara-0.25 medium, and resuspended in 70 µl of PM-Ara-0.25, followed 
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by incubation at 37°C for 10 min. A culture was labeled with 7 µl of Express [35S] 
Protein Labeling Mix (1.175 Ci/mmol, Perkin Elmer) for 1 min at 37°C. The labeling was 
quenched by the addition of 0.5 ml of CM (lacking chloramphenicol) and a chase, also at 
37°C. Samples (0.1 ml) were withdrawn at indicated times during chase and mixed with 80 
µl of TDS buffer (1% SDS, 5 mM dithiothreitol (DTT), 50 mM Tris-HCl, pH 7.4) 
containing “complete protease-inhibitor mixture” (Roche), followed by immediate freezing 
of samples in liquid nitrogen. Frozen samples were directly heated at 95°C for 10 min, and 
thereafter processed and analyzed identically to pulse-chase samples described above. 
 
Pulse-chase assays with immunoprecipitation 
E. coli CAG12184, and pKP73 (Table S1) carrying pKP458 or pKP459 (Table S2) 
were grown at 37°C overnight in LB supplemented with Amp (50 µg/ml). Cultures were 
diluted 1:200 in fresh LB and grown until A600 of ~0.5. A resulting culture (7 ml) was 
centrifuged at 5000g for 5 min at room temperature, washed three times with 1 ml samples 
of pre-warmed PM-Ara-0.1 medium (containing 0.1% arabinose), and resuspended in 70 µl 
of PM-Ara-0.1, followed by incubation at 37°C for 10 min. Cultures were then pulse-
labeled with 7 µl of Express [35S] Protein Labeling Mix (1.175 Ci/mmol, Perkin Elmer) for 
60 sec at 37°C. The labeling was quenched by the addition of 0.5 ml of Chase-Medium 
(CM: M9 medium, pH 7.0, 0.5% glycerol, 0.25% glucose, 0.1 mM CaCl2, 2 mM MgSO4, 
Methionine/Cysteine-free Synthetic Complete (SC) Mixture (Sunrise Science Products), 
0.5 mg/ml unlabeled Met, 0.5 mg/ml unlabeled Cys). Chases were carried out also at 37°C. 
Samples (0.1 ml) were withdrawn at indicated times during chase and mixed with 80 µl of 
TDS buffer (1% SDS, 5 mM dithiothreitol (DTT), 50 mM Tris-HCl, pH 7.4) containing 
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“complete protease-inhibitor mixture” (Roche), followed by immediate freezing of 
samples in liquid nitrogen. For further analyses, one volume of 2x-SDS-PAGE sample 
buffer was added to a frozen sample, followed by heating at 95°C for 10 min. They were, 
thereafter, briefly vortexed and centrifuged at 12,000g for 5 min. Supernatants were diluted 
with 10 volumes of TNN buffer (0.5 % NP40, 0.25 M NaCl, 5 mM Na-EDTA, 50 mM 
Tris-HCl (pH 7.4), containing “complete protease-inhibitor mixture” (Roche)), and 
processed for immunoprecipitation. 5 µl of each “time-zero” sample were spotted on 
Whatman 3MM filters and processed for measurements of CCl3COOH-insoluble 35S as 
described above. 5.5x106 35S cpm of each of the time-zero samples, and equal volumes of 
the following time points for each pulse-series were processed for immunoprecipitation, 
using magnetic beads with immobilized anti-flag antibody M2 (Sigma; 7 µl of settled beads 
for each sample). The samples were incubated with rocking at 4°C for 3 hrs, followed by 
four washes of the beads in TNN buffer, resuspension of pellets in 20 μl of SDS-sample 
buffer, incubation at 95°C for 5 min, and the removal of beads. The resulting samples were 
fractionated by SDS-PAGE using NuPAGE 4-12% Bis-Tris gradient gels, followed by 
autoradiography and quantification using PhosphorImager (Molecular Dynamics, 
Sunnyvale, CA). 
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Figure 2.1. The working model of fMet/N-degrons. (A) Pretranslational 
enzymatic steps that result in formyl-Met (fMet) becoming the first residue of a nascent 
bacterial polypeptide. MetRS, Met-tRNA synthetase. IF proteins, initiation factors. (B) 
Translating ribosomes, with reversibly associated (not depicted) deformylase (PDF) and 
Met-aminopeptidase (MetAP) competing for their overlapping binding sites near the exit 
from the ribosomal tunnel. High-affinity binding by the TF chaperone to a nascent 
polypeptide chain occurs once its length exceeds ~100 residues, usually after 
deformylation of N-terminal Met. A nascent chain, depicted unfolded in this diagram, 
tends to become unstably folded as it emerges from the tunnel. The rate of the MetAP-
mediated removal of the deformylated N-terminal Met residue depends on the identity of 
a residue at position 2. (C-E) Self-explanatory descriptions of the working model of 
fMet/N-degrons. See the main text for additional details and relevant citations. 
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Figure 2.2. Pulse-chase analyses in wild-type and formylation-lacking fmt 
E. coli in the absence or presence of actinonin, an inhibitor of deformylation. (A) 
Wild-type E. coli were pulse-labeled with 35S-methionine/cysteine for 1 min, followed by 
a chase (in the presence of chloramphenicol, a translation inhibitor) for indicated times, 
extraction of proteins, SDS-PAGE, and autoradiography. Pulse-chases were carried out 
either in the absence of actinonin (lanes 1-3) or in the presence of increasing 
concentrations of actinonin (lanes 4-12). Molecular masses of protein markers are 
indicated on the left. (B) Same as in A but pulse-chases were carried out in the absence of 
chloramphenicol in wild-type cells (lanes 1-9) and congenic fmt E. coli (lanes 10-18). 
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Figure 2.3. Analyses of reporter proteins in wild-type and formylation-
lacking fmt E. coli. (A) Design of the P1T2 (D21-11-eK-ha-Ura3) reporter protein. The 
term P1T2 (protein-1 containing Thr at position 2) denotes a chimeric reporter containing 
the indicated N-terminal segments upstream of the 267-residue S. cerevisiae Ura3 
moiety. Arrowheads indicate deformylation of N-terminal fMet by the PDF deformylase 
and the subsequent removal of Met by MetAP. See the main text for details. (B) Same as 
in A but the otherwise identical P1T2D reporter contains Asp (D) at position 2. The rate of 
PDF-mediated deformylation of N-terminal fMet with Asp at position 2 is at least 10-fold 
lower than the rate of deformylation with Thr at position 2. Another difference between 
P1T2 and P1T2D is the retention of N-terminal Met in P1T2D. See the main text for details 
and citations. (C) The use of ubiquitin (Ub) fusions to generate P1T2 and P1T2D through 
the removal of the N-terminal Ub moiety by the S. cerevisiae Ubp1 deubiquitylase 
expressed in E. coli. (D) Immunoblotting analyses, after SDS-PAGE, of the P1T2 reporter 
protein expressed in fmt (lane 1), wild-type (lane 2) and fmt def (lane 3) E. coli. Lanes 4-
6, the corresponding total protein patterns (Coomassie staining). Lane 7, molecular mass 
markers. (E) Immunoblotting analyses, after SDS-PAGE, of the P1T2 and P1T2D reporters 
expressed from the Para promoter in wild-type E. coli (lanes 1-4), and of the Ub fusions 
Ub-P1T2 and Ub-P1T2D in wild-type E. coli expressing the S. cerevisiae Ubp1 
deubiquitylase (lanes 5-8). (F) Same as in E, but independent experiments, in addition to 
expressing Ub-P1T2 and Ub-P1T2D in the absence of coexpressed yeast Ubp1 (lanes 9-12). 
See the main text for details and citations. 
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Figure 2.4. Formylation-dependent selective destabilization of PpiB-based 
reporter proteins. (A) Diagram of the expression cassette in which two identical tandem 
Para promoters express the C-terminally flag-tagged PpiB reference protein PPiB୵୲୑୚୘୊ f 
and the reporter protein MYFYPpiBf-Ub (reporter-1). The latter differs from PPiB୵୲୑୚୘୊ f by 
three amino acid residues adjacent to N-terminal fMet, and by the presence of C-terminal 
Ub moiety, added to make the two proteins distinguishable by size. (B) Lanes 1-6, 
formylation-lacking fmt E. coli were pulse-labeled with 35S-methionine/cysteine for 1 
min, followed by a chase (in the absence of chloramphenicol) for indicated times, 
extraction of proteins, immunoprecipitation with a monoclonal anti-flag antibody, SDS-
PAGE, and autoradiography. Lanes 7-12, same but in wild-type E. coli. (C) Same as in 
A, with the reference PPiB୵୲୑୚୘୊ f and the reporter MDDDPpiBf-Ub (reporter-2), which 
differed from MYFYPpiBf-Ub in A and B by three residues (Asp-Asp-Asp) downstream 
from N-terminal fMet. (D) Same as in B but with PPiB୵୲୑୚୘୊ f and MDDDPpiBf-Ub 
(reporter-2). See the main text for the logic and details of these experiments. 
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Figure S2.1. The Arg/N-End Rule Pathway and the Ac/N-End Rule Pathway. N-
terminal residues are indicated by single-letter abbreviations. A yellow oval denotes the 
rest of a protein substrate. The N-end rule pathway recognizes proteins containing 
N-terminal degradation signals called N-degrons, polyubiquitylates these proteins and 
thereby causes their degradation by the 26S proteasome. Recognition components of the N-
end rule pathway are called N-recognins. Eukaryotic N-recognins are E3 ubiquitin (Ub) 
ligases that can target N-degrons. The main determinant of an N-degron is a destabilizing 
N-terminal residue of a protein. In eukaryotes, the N-end rule pathway consists of two 
branches, described in panels A and B. 
(A) The Arg/N-end rule pathway in S. cerevisiae [1-5]. The prefix “Arg” in the 
pathway’s name refers to Nt-arginylation of N-end rule substrates. The Arg/N-end rule 
pathway targets specific unacetylated N-terminal residues. It is mediated by the Ubr1 N-
recognin, a 225 kDa RING-type E3 Ub ligase and a part of the targeting complex 
containing the Ubr1-Rad6 and Ufd4-Ubc4/5 holoenzymes. The Ubr1 (N-recognin) 
component of this complex recognizes (binds to) the “primary” destabilizing N-terminal 
residues Arg, Lys, His, Leu, Phe, Tyr, Trp and Ile, as well as the unmodified N-terminal 
Met residue, if Met is followed by a bulky hydrophobic (Ф) residue [5]. The terms 
“secondary” and “tertiary” refer to the indicated enzymatic modifications of specific N-
terminal residues. N-terminal Cys can be arginylated by the Ate1 arginyltransferase 
(R-transferase) only after the oxidation of Cys to Cys-sulfinate or Cys-sulfonate, in 
reactions that involve nitric oxide (NO) and oxygen [2-4, 6, 7]. Regulated oxidation of N-
terminal Cys takes place in multicellular eukaryotes but not in fungi such as S. cerevisiae, 
which apparently do not produce NO under normal conditions. 
(B) The Ac/N-end rule pathway in S. cerevisiae [3, 5, 8-10]. This pathway 
recognizes substrates through their Nα-terminally acetylated (Nt-acetylated) residues. The 
corresponding degradation signals and E3 Ub ligases are called Ac/N-degrons and 
Ac/N-recognins, respectively. Red arrow on the left indicates the removal of N-terminal 
Met by Met-aminopeptidases (MetAPs). N-terminal Met is retained if a residue at position 
2 is larger than Val [11-13]. The term “secondary” refers to the requirement for a 
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modification (Nt-acetylation) of a destabilizing N-terminal residue before a protein can 
be recognized by an Ac/N-recognin. 
(C) and (D) The bacterial Leu/N-end rule pathway, in Escherichia coli (C) and in 
Vibrio vulnificus (D) [14-32]. The Aat L/F-transferase conjugates (largely) Leu to N-
terminal Arg or Lys. N-end rule substrates bearing primary (bulky hydrophobic) 
destabilizing N-terminal residues are recognized by the ClpS N-recognin and are delivered 
for degradation to the ClpAP protease. In V. vulnificus, the Leu/N-end rule pathway 
contains both the Aat L/F-transferase and the Bpt L-transferase. As a result, N-terminal 
Asp and Glu, which are not destabilizing residues in E. coli, function as secondary 
destabilizing residues in V. vulnificus [16].  
Regulated degradation of proteins or their natural fragments by the N-end rule 
pathway mediates a broad range of biological functions (refs. [2-5, 8-10, 31] and refs 
therein). 
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Table S2.1 Bacterial strains used in this study. 
E. coli 
strains 
Genotype Source or Ref. 
MG1655 F- - rph-1 [33] 
MG-D F- - rph-1 Δ(def-fmt)::cm ΔgloB::frt Gift from D. 
Mazel 
DH5α φ80 lacZM15 endA1 recA1 gyrA96 thi-1 
hsdR17  
(rk- , mk- ) relA1 supE44 deoR ∆(lacZYA–
argF)U169 
Promega 
CAG12184 - rph-1 tolC210::Tn10 (tet) [34] 
KPS73 - rph-1 tolC210::Tn10 (tet) Δfmt ::Km This study 
KPS74 - rph-1 tolC210::Tn10 (tet) Δdef-Δfmt ::Km This study 
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Table S2.2 Plasmids used in this study. 
Plasmid name Description Source or Ref. 
pJT184 CmR; pACYC184-based plasmid with 2.8-kb BamHI/SalI 
insert containing S. cerevisiae Ubp1. 
[14] 
pBADET ApR; pBAD2-based plasmid containing arabinose-inducible 
promoter and expanded multiple cloning site. 
Gift from 
V. Ksenzenko  
pACYC177  ApR, KmR; low copy vector  
containing p15A repl. origin. 
[35, 36] 
pKD46  ApR; ts replication (repA101ts); encodes lambda Red genes 
o, bet, gam); native terminator (tL3) after exo gene; arabinose-
nducible promoter for expression (Para); encodes araC for 
epression of the Para promoter. This plasmid was used for 
chromosomal deletions of specific genes. 
[37] 
pKD3 ApR, CmR; R6K origin-based plasmid containing cat-cassette 
ed by FRT sites. This plasmid was used as a template in PCR to 
create gene-specific cat-cassettes. 
[37] 
pCH178  ApR; p314CUP1-based plasmid expressing Ub-CK-eK-ha-
Ura3. 
[9] 
pKP249  ApR; pBADET-based plasmid expressing P1T2-eK-ha-Ura3 
from Para promoter. 
This study 
pKP250  ApR; pBADET-based plasmid expressing P1T2D-eK-ha-Ura3 
from Para promoter. 
This study 
pKP251  ApR; pBADET-based plasmid expressing Ub-P1T2-eK-ha-
Ura3 from Para promoter. 
This study 
pKP252  ApR; pBADET-based plasmid expressing Ub-P1T2D-eK-ha-
Ura3 from Para promoter. 
This study 
pKP257  ApR; pACYC177-based plasmid expressing P1T2-eK-ha-Ura3 
from PKmR promoter. 
This study 
pKP258 ApR; pACYC177-based plasmid expressing P1T2D-eK-ha-Ura3 
from PKmR promoter. 
This study 
pKP286  ApR; pBADET-based plasmid expressing PpiB-8his-flag from 
Para promoter. 
This study 
pKP287 ApR; pBADET-based plasmid expressing PpiBV2D-8his-flag 
from Para promoter. 
This study 
pKP335  ApR; pBADET-based plasmid expressing PpiB-8his-flag-Ub-
PpiB-8his-flag from Para promoter 
This study 
pKP458  ApR; pBADET-based plasmid expressing MVTVPpiB-8his-flag 
d MDDDPpiB-8his-flag-Ub from two identical and independent  
Para promoters. 
This study 
pKP459 ApR; pBADET-based plasmid expressing MVTVPpiB-8his-flag 
d MYFYPpiB-8his-flag-Ub from two identical and independent  
Para promoters. 
This study 
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CHAPTER 3: 
THE ARG/N-END RULE PATHWAY AS A REGULATOR OF 
PROCESSES THAT CAN CAUSE EPILEPSY 
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Introduction 
Epilepsy is the most common neurological disorder, occurring at the rate of 5 to 10 
per 1000 people  [1]. Epileptic seizures occur in many variations, with different levels of 
severity. Susceptibility to epilepsy depends on a variety of factors, including the age and 
gender of  patients and their specific health problems [2]. Although there are drugs to 
alleviate the symptoms, about one third of patients become resistant to anti-epileptic drugs. 
Some patients, including those with drug-resistant epilepsy, have to undergo brain surgery, 
often with lifelong side effects [3, 4]. These difficulties make it particularly important to 
understand molecular causes and risk factors in epileptic seizures.  
In this chapter, we summarize the current understanding of epilepsy, with an 
emphasis on one known risk factor for seizures: dysregulation of Ca2+ signaling. Increased 
Ca2+ transients, as a result of over-excitation of neurons, activate intracellular proteases such 
as Ca2+-dependent calpains, leading to cellular injury and death. We demonstrate here that 
Ate1-/- mice, which lack the arginylation branch of the Arg/N-end rule pathway (Fig. 1.2), 
are not only  hypersensitive to treatments that can induce epileptic seizures but also suffer 
higher levels of brain damage as a result of seizures. These and related findings, to be 
described below, indicate that at least the arginylation branch of the Arg/N-end rule pathway 
is, operationally, a repressor of epileptic seizures.  
One plausible and testable explanation of this function of the Arg/N-end rule pathway 
is its previously demonstrated ability to conditionally destroy the Rgs4, Rgs5 and Rgs16 
proteins., All three of these proteins are down-regulators of Gα subunits of specific G 
proteins, by virtue of the ability of these (and other) RGS proteins to increase the otherwise 
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low GTPase activity of Gα subunits [5]. Rgs4 is the most prominently and broadly 
expressed member of this set of three RGS proteins, all of which are expressed in the brain. 
A partially repressed signaling by metabotropic G-protein-coupled receptors (GPCRs) can 
result in longer durations and/or higher frequencies of Ca2+ transients. An example of this 
was demonstrated in the presynaptic neurons of embryonic chick dorsal root ganglia. 
Specifically, an intracellular injection of a small amount of purified Rgs4 inhibits the ability 
of these neurons to decrease intracellular Ca2+ though their metabotropic norepinephrine 
receptors [6]. We envision a similar dysfunction in Ate1-/- mice, in which the levels of the 
normally short-lived Rgs4 (Nt-arginylated by Ate1 and destroyed by the rest of the Arg/N-
end rule pathway) are greatly elevated, as described below. 
 
Seizures are monitored by EEGs 
With humans as well as in in animal models, epileptic seizures are diagnosed using 
electroencephalograms (EEGs). To carry out an EEG recording, electrodes are placed on the 
scalp or are inserted intracranially. EEG readouts are plots of voltage differences between 
two electrodes over time. Since there are many ways of placing electrodes, there are many 
ways (called channels) of taking EEGs. The channels can be local (a region of the brain) or 
global (involving the whole brain). In normal human adults, there are several physiologically 
relevant EEG frequencies: the delta rhythms (<4 Hz), the theta rhythms (4-8 Hz), the alpha 
rhythms (8-14 Hz), the beta rhythms (14-30 Hz), and the gamma rhythms (> 30Hz). Epileptic 
seizures result in abnormal EEG rhythms. Measurements of EEG rhythms have shown that 
epileptic seizures are initiated in a small brain region (called focus) and spread out to a larger 
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region, sometimes to the entire brain. Some seizures may have more than one focus. 
Seizures are categorized by where they initiate and where they tend to spread. Two common 
types are absence seizures and temporal lobe epilepsy (TLE). 
Absence seizures are a type of generalized seizures. These seizures involve cortical-
thalamus circuits [7-9]. Seizures are initiated from the thalamus and spread to the cortical 
areas (although there is also evidence that the somatosensory region of the cortex can initiate 
seizures) [9]. Once initiated, these epileptic states spread between the cortex and the 
thalamus. Their EEGs are characterized by the so-called 3-Hz spike and wave complex, 
which are detected using an algorithm referred to as wavelet transformation [10]. 
Temporal lobe epilepsy (TLE) is an example of partial seizures. It often occurs as a 
result of hippocampal sclerosis, a damage in that region of the brain manifested as 
hippocampal scars. They are caused by injuries such as stroke, head trauma, or prolonged 
seizures. [11-13]. For some patients, surgical removal of the damaged hippocampus prevents 
recurrent seizures. However, about 30% of patients who undergo such surgeries still suffer 
from seizures [14]. Since partial seizures occur in 60% of epileptic patients and TLE is the 
most common partial seizure, TLE is the focus of the bulk of research on epileptic seizures. 
TLE is modeled in rodents that are treated with chemoconvulsants such as kainic acid 
(kainate; KA). KA treatments lead to hippocampal injuries and spontaneous recurrent 
seizures, mimicking the human disorder [14, 15]. 
TLE hippocampal EEGs show disruption of theta rhythms. KA-treated rodents have 
isolated spike, spike-and-wave, or poly-spikes at 1-3 Hz frequency [11, 12]. These seizures 
are usually initiated from the hippocampus [16]. They can also be initiated from the 
amygdala, the entorhinal cortex, and part of the thalamus [7]. They spread, thereafter, to other 
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limbic regions. In severe cases, they spread to the prefrontal cortex, leading to generalized 
seizures. As with absence seizures, TLE can be reliably diagnosed using specific 
mathematical transformations of raw EEG data [17]. 
 
Molecular understanding of epilepsy is still far from detailed  
While EEGs allow us to diagnose epilepsy, they do not, by themselves, illuminate 
the molecular causes and genetic factors that increase susceptibility for seizures. Genetic-
predisposition studies showed that epilepsy is facilitated by a number of distinct genetic 
defects rather than by one major defect [18]. Patients with absence seizures usually have 
mutations in genes encoding voltage-gated Ca2+ channels [19, 20], the GABAA channel [21-
23], the NMDA receptor [23], voltage-gated K+ channels [2], or voltage-gated Na+ channels 
[24-27].  
Patients with TLE do not seem to have a common set of genetic defects. There are 
clinical reports of a family of epileptic patients who shared specific mutations of the leucine-
rich glioma-inactivated 1 (LGI1) gene. There are also reports of patients who have inherited 
mutations of their voltage-gated Na+ channels. However, the number of patients with these 
mutations are too few to link these mutations, reliably, to TLE [28].  
In the absence of a clear understanding of epilepsy, there are several hypotheses about 
its causes. One idea is that seizures result from an imbalance in activity among the excitatory 
and inhibitory neurons. This imbalance may result from dysfunctions in the channels and 
receptors that modulate synaptic transmissions. Another idea is that seizures are caused by 
cell death and inflammation in the brain that result in scars such as TLE hippocampal 
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sclerosis. Other causes of epilepsy may stem from glial cell dysfunctions or pathological 
Ca2+ transients. We now discuss these hypotheses in some detail, and thereafter consider a 
specific role that the Arg/N-end rule pathway plays in regulating events that are relevant to 
epilepsy, with an emphasis on the G protein regulators Rgs4, Rgs5 and Rgs16. 
 
The glutamatergic and GABAergic receptors are implicated in epilepsy 
In the brain, a neuron typically receives thousands of synaptic inputs from other 
neurons. In turn, a neuron sends output signals to many other neurons. Presynaptic neurons 
are categorized as either excitatory or inhibitory. Excitatory neurons make a postsynaptic 
neuron more likely to generate an action potential. Inhibitory neurons make a postsynaptic 
neuron less likely to generate an action potential. By working together, they form circuits 
carrying signals and making long-term changes to the probabilities of action potentials by 
specific neurons. The main excitatory neurons are the glutamatergic neurons. The main 
inhibitory neurons are the GABAergic neurons. Hippocampal circuits consist of both 
glutamatergic pyramidal neurons and GABAergic neurons. Similarly, the cortical-thalamus 
circuits comprise both GABAergic interneurons and glutamatergic neurons [8, 9, 22, 29, 30]. 
Glutamate is the principal neurotransmitter of glutamatergic neurons. Glutamate 
activates two classes of receptors: ionotropic ones (NMDA, AMPA, and kainate receptors) 
(iGluRs) and metabotropic receptors (mGluRs). The latter are G protein-coupled receptors 
(GPCRs). They belong to the same family (family C) as the metabotropic GABAB receptor 
that is described below. mGluRs are categorized into three main groups, based on their 
sequelogy (sequence similarity [31]) and specific molecular mechanisms [32]. Group I 
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includes mGluR1 and mGluR5. Group II includes mGluR2 and mGluR3. Group III 
includes mGluR4, mGluR6, mGluR7, and mGluR8. Like other GPCRs from family C, these 
mGluRs function as dimers. mGluR5, for example, is known to form a heterodimer with 
mGluR1. Interestingly, mGluR5 also forms heterodimers with the adenosine A2A receptor or 
the dopamine D2 receptor [33]. Hippocampal and cortical-thalamus circuits express all of 
these mGluRs and iGluRs [8, 34, 35]. 
iGluRs receptors mediate the flows of Ca2+ and Na+ into cells. When iGluRs are 
located on postsynaptic neurons, the resulting ion flow “excites” a cell, i.e., it increases the 
probability of action potential. When iGluRs are located on presynaptic neurons, the 
receptor-mediated ion flows facilitate the release of neurotransmitters [35]. While iGluRs 
play the main role in synaptic excitation, specific mGluRs modulate synaptic transmissions 
[32]. Group I mGluRs increase postsynaptic neuron excitability. They activate the Gαq/11 
family of G proteins to mediate Ca2+ signaling [36, 37]. In contrast, group II and group III 
mGluRs decrease presynaptic neuron activities. They activate the Gαi/o family proteins to 
inhibit voltage-gated Ca2+ channels and to activate G protein-coupled inward rectifying K+ 
(GIRK) channels. This reduces Ca2+ influx and increases K+ efflux, hyperpolarizing the 
neurons. Furthermore, group II and group III mGluRs inhibit the synaptic SNARE complex, 
reducing presynaptic neurotransmitter exocytosis [8, 35].  
All iGluRs and mGluRs are implicated in epilepsy. iGluR agonists such as NMDA 
and KA induce seizures [38-40]. Group I mGluRs are involved in audiogenic seizures in 
fragile X syndrome model mice [36, 37] and their antagonists alleviate absence seizures [41]. 
The roles of group II and group III mGluRs in epilepsy are more complicated, as their 
agonists and antagonists have mixed effects on epilepsy. But in general, agonists of group II 
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and group III mGluRs inhibit seizures and protect neurons from excitotoxicity [8, 41, 42].  
 GABA is the main inhibitory neurotransmitter in GABAergic neurons. Analogously 
to glutamate, GABA activates two major types of receptors: the fast acting GABAA and 
GABAC ionotropic channels, as well as the slower acting metabotropic GABAB receptor. 
GABAA and GABAC are chloride-ion (Cl-) channels. GABA activation leads to Cl- influx, 
hyperpolarizing neurons and thereby decreasing the probability of action potentials. 
Metabotropic GABAB receptors work similarly to group II and group III mGluRs. They 
activate Gαi/o family G proteins to inhibit voltage-gated Ca2+ channels, activate GIRKs, and 
reduce the release of neurotransmitters [43-45]. Mutations of genes encoding GABAA 
receptors increase the risk of absence seizures [23]. GABAB agonists and antagonists affect 
the severity of seizures depending on the animal model [46, 47]. 
Glutamatergic and GABAergic neurons work together to fine-tune neuronal circuits. 
Dysfunction in the glutamatergic and GABAergic receptors can lead to excessive glutamate 
release and, consequently, excessive Ca2+ transients. The resulting higher levels of 
intracellular cytosolic Ca2+ hyper-activate both specific kinases, nitric oxide synthases, and 
Ca2+-dependent calpain proteases. These events can result in either necrotic or apoptotic cell 
death, as described below. 
 
Astrocytes are implicated in epilepsy 
In addition to comprising circuits of excitatory and inhibitory neurons, brains also 
contain other cell types, referred to as glial cells. Astrocytes are glial cells that play major 
roles in the maintenance and regulation of neuronal circuits. Dysfunction of astrocytes can 
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also facilitate epileptic seizures. Like the glutamatergic neurons, astrocytes relies on 
specific mGluRs for many of their functions. 
Astrocytes detect synaptic glutamate levels through their mGluRs to modulate 
glutamate concentration and synaptic transmission [48-51]. For example, mGluR5 works 
with the ATP receptor P2Y1 to induce astrocyte release of glutamate and D-serine. The 
released glutamate activates presynaptic NMDA receptor to increase neurotransmitter 
release [52].  D-serine binds to postsynaptic NMDA receptor to increase its probability of 
activation, thereby increasing neuron long-term potentiation  (LTP) [53]. In addition, 
mGluRs protect astrocytes from Ca2+-mediated excitotoxicity [42]. 
Another role of astrocytes is their control of the interstitial volume (extracellular 
space; ECS) and K+ concentration. Small ECS tends to increase K+ concentration and the 
incidence of seizures [54]. ECS is regulated by volumes of individual astrocytes through the 
aquaporin AQP4 and the K+ channel Kir4.1 which work together to control water and K+ 
flows in the synapse [52]. This regulation is influenced by mGluRs, as astrocytes can be 
shown to swell upon activation of mGluRs [55].  
Astrocytes also regulate specific cerebrovascular structures and modulate cerebral 
blood flow in part through their mGluRs [56-59]. To maintain the blood-brain barrier (BBB), 
astrocytes rely on other GPCRs. For example, astrocytes release the Sonic Hedgehog (Shh) 
protein, which causes capillary endothelial cells to upregulate tight junction proteins [60, 61]. 
On these endothelial cells, Shh activates the Hedgehog receptor to alleviate the inhibition of 
Smo, a GPCR. Smo activates specific Gli transcription factors that activate, in turn, specific 
gene regulons. Breakdown of the BBB leads, among other things, to thrombin leakage into 
the brain. Thrombin activates the protease activated receptor (PARs) [62]. PARs are GPCRs 
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that activate either the Gαq/11, the Gαi/o, or the Gα12/13 proteins. Not much is known about 
these receptors, but activation of PAR1 is reported to increase neuron excitability, neuronal 
death, or astrocyte proliferation [63, 64]. 
 
Purinergic receptors and inflammation are implicated in TLE (temporal lobe 
epilepsy) 
Astrocytes also play a role in hippocampal sclerosis. These tissue scars comprise, in 
particular, dead neurons and live but altered cells, such as “transformed” astrocytes, which 
undergo a process called astrogliosis. Mildly transformed astrocytes upregulate a variety of 
proteins, including GFAP and extracellular matrix proteins [65, 66]. They also upregulate 
mGluRs, including mGluR3, mGluR5, and mGluR8, and cytokines such as TGFβ, TNFα, 
IL-1β, and IL-6. Severely transformed astrocytes  proliferate and form long-lasting scars that 
inhibit axon regeneration [56]. At the same, not all manifestations of scars are physiologically 
detrimental. For example, scars can form borders protecting neuronal tissue against 
inflammatory cells of the immune system. 
Astrogliosis is regulated by extracellular ATP and adenosine through purinergic 
receptors [67, 68]. ATP is released, in particular, from damaged cells, including transformed 
astrocytes. These astrocytes upregulate the connexin-43 hemichannel, increasing ATP efflux 
[69]. Extracellular ATP activates P2 receptors. There are two types of P2 receptors, 
ionotropic P2XRs and metabotropic P2YRs. P2XRs receptors allow influxes of Na+, K+, and 
Ca2+. The P2YR1, 2, 4, 6, and 11 receptors activate Gαq proteins for Ca2+ signaling, while the 
P2YR12, 13, and 14 receptors activate the Gαi proteins to inhibit adenylyl cyclase. 
  
108
Extracellular ATP is gradually converted into adenosine, which activates specific 
adenosine receptors. These receptors (A1 and A3), in turn, activate the Gαi/o G proteins, while 
the A2A and A2B receptors activate Gαs G proteins.  
Astrocytes sense cell damage through activation of their P2YR receptors by 
extracellular ATP. This activation induces astrocytes to release glutamate. Glutamate and 
ATP work together to induce astrocytes to release the cytokines TNFα, IL-1β, and IL-6 [70, 
71]. These cytokines worsen scar formation [72]. First, they attract and activate microglial 
cells (resident macrophages of the brain). Second, the released cytokine TNFα activates TNF 
receptors. TNF receptor activation, along with activation of the mGluR5 and P2Y1R 
receptors, induce astrocytes to release even more glutamate and ATP, resulting in positive 
feedback. Third, the interleukin IL-1β disrupts BBB permeability, causing 
neuroinflammation [61, 73]. Fourth, inflammatory cytokines reduce seizure threshold vis-à-
vis the level of neuronal excitation [54, 74-76], because TNFα and IL-1β affect the activity 
of neuronal voltage-dependent Ca2+ and K+ channels as well as the AMPA, NMDA, and 
GABA ionotropic receptors [77]. For example, it has been shown that blocking IL-1β 
signaling reduces severity of a seizure [78].  
While extracellular ATP increases astrogliosis, the same ATP tends to be protective 
vis-à-vis neurons. Activation of the neuronal P2YR channel inhibits Ca2+ signaling and 
neurotransmitter exocytosis, decreasing excitotoxicity [79]. This may explain why ATP 
receptor agonists and antagonists have mixed effects on TLE-type epilepsies [80]. In sum, 
the roles of ATP receptors in regulating events linked to epilepsy remains to be better 
understood [79, 81].  
Adenosine also has different effects on astrocytes and neurons. A2A receptor 
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activation increases astrogliosis and leads to neuronal apoptosis [82]. Not much is known 
about the A3 receptor, whose activation can be either protective or seizure-inducing. On the 
other hand, the A1 adenosine receptor plays a major neuroprotective function. On presynaptic 
neurons, the A1 receptor inhibits Ca2+ channels, activates the GIRKs, and down-regulates 
the release of neurotransmitters. Through the A1 receptor, adenosine suppresses seizures and 
protects neurons from excitotoxicity [35, 82-85].  
 
The Arg/N-end rule pathway as a repressor of epileptic seizures 
As described above, the brain relies on various GPCRs and Ca2+ signaling to 
modulate synaptic transmissions, maintain cerebrovascular structures, and control 
neuroinflammation. The Arg/N-end rule pathway plays a role in this regulation, in part 
through its Ate1-mediated arginylation branch (Fig. 1.2). One role of the Ate1 R-transferase 
is to mediate the conditional degradation of three G-protein down-regulators, Rgs4, Rgs5, 
and Rgs16 [86, 87].  
Rsg4, the most broadly and highly expressed RGS among the above three RGS 
proteins, is present in both neurons and astrocytes [88, 89]. It acts on the Gαi and Gαq family 
of the G proteins and down-regulates their activity by increasing the otherwise weak intrinsic 
GTPase activity of these Gα proteins In particular, Rgs4 down-regulates the activity of the 
mGluR1, mGluR5, GABAB, and A1 receptors, thus impacting, simultaneously, a variety of 
brain functions [90, 91]. 
 In the hippocampus, a neuron that emitted an action potential becomes 
hyperpolarized and enters the refractory period. This phase depends on the Ca2+-activated K+ 
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efflux. The outflow of K+ is inhibited when mGluR5 is activated. Rgs4 down-regulates 
the activity of mGluR5, thereby allowing hippocampal neurons to hyperpolarize [92]. In the 
paraventricular nucleus of the hypothalamus, postsynaptic neurons communicate with 
presynaptic neurons through glucocorticoids to inhibit the release of GABA from presynaptic 
neurons, and thereby to minimize the extent of long-term depression. Glucocorticoid release 
from postsynaptic neurons is upregulated by mGluR5. Rgs4 also down-regulates 
postsynaptic mGluR5 to maintain long-term depression [93]. In the prefrontal cortex and the 
hypothalamus, Rgs4 was shown to interact with the GABAB receptor complex [94]. GABAB 
receptor activates K+ channels and inhibit Ca2+ channels to hyperpolarize neurons [95-98]. 
Rgs4 down-regulates GABAB to increase the excitability of neurons [96, 98]. Therefore, 
predictably, fragile X-syndrome model mice that in addition lack Rgs4 are less susceptible 
to audiogenic seizures [99, 100]. In cortical neurons, Rgs4 was shown to interact with 
neurabin to inhibit the adenosine A1 receptor [101]. Adenosine is known to suppress seizures 
through the A1 receptor [102]. Inhibiting Rgs4 decreases KA-induced seizures in mice [101].  
Effects of Rgs4 on other GPCRs are less well understood. Rsg4 down-regulates 
P2YR1 and P2YR12 receptors in vitro, suggesting its role in astrocyte-mediated release of 
cytokines [103]. RGS4 interacts with PAR1 in COS7 cells, suggesting its involvement in 
thrombin- mediated neuroinflammation [104]. As for Rgs5, it is significantly expressed in 
the vascular structures [105]. In particular, Rgs5 represses Smoothened (Smo), a GPCR-like 
receptor that is part of the hedgehog signaling pathway, in murine embryonic mesenchymal 
C3H10T1/2 cells [106]. Rgs5 may act to weaken the blood-brain barrier (BBB) by reducing 
the ability of capillary endothelial cells to express tight junction proteins [107]. The third 
RGS protein, Rgs16, that is conditionally Nt-arginylated and destroyed by the Arg/N-end 
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rule pathway, is expressed in the suprachiasmatic nucleus of the hypothalamus [108] and 
in activated T-cells in germinal centers, [109] suggesting that Rgs16 may regulate circadian 
rhythm and adaptive immunity [91]. In sum, and focusing on Rgs4, it is already clear that 
mice in which the levels of (at least) Rgs4 are abnormally high suffer a number of 
neurological defects. 
Yet another important role of the Ate1 R-transferase and the rest of the Arg/N-end 
rule pathway is to mediate the degradation of pro-apoptotic protein fragments that are 
generated by non-processive proteases such as calpains and caspases in the presence of 
pathologically high levels of Ca2+ transients [110-113]. Activation of calpains results in a 
large number of intracellular protein fragments [114]. They include pro-apoptotic fragments 
such as Glu-Bak [115]. Some pro-apoptotic fragments such as Asn-Bfl1 [116] and Asp-BclXL 
are produced from cleavages of anti-apoptotic proteins [117]. Thus, activation of calpains 
shifts cells toward a pro-necrotic and/or pro-apoptotic state. This shift is inhibited by the 
Arg/N-end rule pathway and in part by the Ate1 R-transferase as well, because Ate1 Nt-
arginylates and thereby targets for degradation not only Rgs4 but also a subset of natural C-
terminal pro-apoptotic protein fragments that bear Nt-arginylatable N-terminal residues, 
such as N-terminal Asp, Glu or (oxidized) Cys (Fig. 1.2) [110, 111]. Some natural protein 
fragments, such as the cleaved ryanodine receptor Gln-Ryr1 [118], increase Ca2+ influx into 
the cytosol, worsening excitotoxic effects of Ca2+ [119].The Ate1 R-transferase may 
counteract such effects by mediating the degradation of protein fragments bearing Nt-
arginylatable N-terminal residues (Asp, Glu, oxidized Cys), and indirectly N-terminal Asn 
and Gln as well, because these residues are rapidly deamidated by N-terminal amidases 
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Ntan1 and Ntaq1, the most “upstream” components of the Arg/N-end rule pathway (Fig. 
1.2). 
As one would expect, given the above connections between Nt-arginylation and the 
levels of Rgs4, Rgs5 and Rgs16, Ate1-lacking Ate1-/- mice exhibit a large variety of abnormal 
phenotypes. Specifically, unconditionally null Ate1 -/- mice are embryonic lethals, dying on 
embryonic day 15 (E15) [120]. Ate1 -/- embryos exhibit internal bleeding and have defective 
heart and vascular development. Mice with a conditional Ate1 deletion (induced in adult mice 
using the cre-lox system) are viable but also exhibit a number of abnormal phenotypes [121]. 
Specifically, about 15% of mice die upon tamoxifen (TM)-induced deletion/disruption of 
both copies of the Ate1 gene. The surviving mice fail to thrive, in comparison to control 
littermates. These mice are lean, have enlarged brain, heart, and kidney, are strikingly 
hyperkinetic, and are easily startled [121]. 
In the present study, we examined neurological abnormalities of Ate1-/- mice more 
closely, with an emphasis on the possible propensity of these mice to epileptic seizures.  
 
Results and Discussion 
Ate1tetO/-;R26rtTA Mouse Strains  
To complement our previously constructed Ate1flox/-;CaggCreER mouse strains 
[121], we also constructed a doxycycline-inducible Ate1tetO/-;R26rtTA mouse strain.  These  
mice harbor one unconditionally null (deletion/disruption) Ate1− allele (derived, through 
matings, from the previously constructed unconditional heterozygous Ate1+/− mice [120]) 
and one Ate1tetO allele. Mice with Ate1tetO allele had negligible levels of Ate1 R-transferase 
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expression, from that allele, in the absence of doxycycline (Dox) (even in the presence of 
the R26rtTA gene in these mice). However the addition of Dox to mouse food resulted in a 
strong expression of the Ate1 R-transferase from the Ate1tetO allele (Fig. 4.1, Fig. 4.2, and 
Fig. 4.3). 
To construct Ate1tetO/-;R26rtTA mice, the endogenous PAte1 bidirectional promoter 
(previously investigated in our laboratory [122]) was replaced with the Dox-inducible 
(TetO)7PminiCMV promoter to produce the Ate1tetO allele (Fig. 4.2). Heterozygous matings 
among Ate1tetO/+ mice, Ate1+/- mice, and R26rtTA mice were carried out to generate mice of 
the desired genotype [123]. These mice, in addition to containing the Ate1tetO configuration 
at the Ate1 locus, also expressed a modified form of reverse tetracycline/Dox-controlled 
transactivator (rtTA) at the Rosa26 locus. rtTA is a fusion of a TetR mutant (rTetR) and the 
C-terminal activation domain of VP16 of the herpes simplex virus [124]. Upon the addition 
of Dox, rTetR undergoes a conformation change that results in its binding to the tetO DNA 
elements [125]. The activation domain of VP16 attracts host transcription factors to initiate 
transcription (Fig. 4.1) [126]. When Ate1tetO/- ;R26rtTA mice were fed Dox-containing food, 
the single Ate1tetO allele overexpressed Ate1 R-transferase, generating approximately 2-fold 
higher steady-state levels of the Ate1 protein than the levels of Ate1 in wild-type mice (Fig 
4.3). 
To confirm that Dox induces expression of Ate1, immunoblotting analyses, using 
affinity-purified anti-Ate1 antibody, were carried out with extracts of the stomach, pancreas, 
brain, testis, heart, thymus, and ES cells of Ate1tetO/tetO;R26rtTA, Ate1tetO/+;R26rtTA, and 
Ate1tetO/- mice (Fig. 4.3 and Fig. 4.4). Mice that were fed control (Dox-deficient) diet had low 
or negligible Ate1 R-transferase expression in the above tissues, with the exception of the 
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thymus. In contrast, mice that were fed Dox-containing diet had high level of Ate1 R-
transferase expression. In particular, the brains of Ate1tetO/- mice on Dox-deficient diet, 
contained negligible levels of Ate1 R-transferase. The resulting Ate1 R-transferase 
deficiency led to strikingly high steady-state levels of the Rgs4 protein (Fig. 4.4).  
 
Increased susceptibility to epilepsy and increased severity of seizures in Ate1flox/-
;CaggCreER and Ate1tetO/- mice 
To address the role of Ate1 and Nt-arginylation in epileptic seizures, we subjected 
Ate1flox/-;CaggCreER mice, Ate1tetO/- mice, Ate1tetO/-;R26rtTA mice, and their corresponding 
wild-type and heterozygous (control) littermates (Ate1flox/+ mice, Ate1tetO/+ mice, Ate1+/- 
mice, and Ate1tetO/+;R26rtTA mice) to treatments with either NMDA or KA through 
intraperitoneal (IP) injections. Ate1flox/-;CaggCreER mice were made Ate1-deficient through 
tamoxifen (TM) treatment [121]. Ate1tetO/- mice and Ate1tetO/-;R26rtTA mice were fed a Dox-
deficient diet, resulting in negligible activity of their single Ate1 allele. We observed mice 
for 60-120 minutes after injections of either NMDA or KA and scored severity of seizures 
using the Racine scale. Remarkably, all three kinds of Ate1-deficient mice, Ate1flox/-
;CaggCreER mice, Ate1tetO/- mice, and Ate1tetO/-;R26rtTA mice, suffered severe seizures upon 
either NMDA or KA treatments that resulted in mild effects on wild-type (Ate1+/+) and 
heterozygous (Ate1+/-) mice (Fig. 4.5 and Fig. 4.6). In the case of KA treatments on Ate1flox/-
;CaggCreER mice, one of the wild-type mice suffered fatality during seizure skewing the 
average Racine score for control mice (Fig. 4.6). We are investigating more mice to see if 
this is an anomaly or if there are other variables that affect mouse predisposition toward 
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epileptic seizures. For example, the time of day at which the experiment is carried out 
may affect endogenous Ate1 levels due to circadian rhythm regulation.  
Previous studies have shown that in mice treated with KA or NMDA, the more severe 
seizures caused higher extents of brain injury [127, 128]. In these Ate1-deficient, highly 
epileptic mice, we found, using histochemical methods, widespread cell death in the 
thalamus, the hypothalamus, and the hippocampus.  Sections of mouse brains were stained 
with Fluoro-Jade C to detect dead neurons. Fluoro-Jade C is a mixture of the sulfate ester of 
three fluorescein derivatives (see Materials and Methods) that specifically and reliably stains 
dead neurons [127]. TM-treated Ate1flox/-;CaggCreER mice (converted to the Ate1-/-
;CaggCreER genotype in the brain and other tissues) that underwent KA treatment suffered 
a marked increase in cell death in the hippocampus, thalamus, and hypothalamus regions, in 
comparison to KA-treated wild-type mice (Fig. 4.7A, B, and C).  
To observe apoptotic cells using a different method, we performed TUNEL assays 
with the brain sections. While TM-treated Ate1flox/-;CaggCreER mice that underwent KA 
treatment exhibited a minor increase in hippocampal apoptosis in comparison with KA-
treated wild-type mice (Fig 4.8A), we observed a moderate increase of apoptosis in the 
thalamus and a major increase of apoptosis in the hypothalamus of TM-treated Ate1flox/-
;CaggCreER mice, in comparison with  KA-treated wild-type mice (Fig. 4.8B and C). The 
seemingly lower extents of apoptosis observed using conventional TUNEL assay may stem 
from a lower sensitivity of this assay, in comparison, e.g., to Fluoro-Jade C staining (Fig. 
4.7). We plan to investigate cytological cell death patterns further using APO™-BrdU 
TUNEL assay. This version of a TUNEL assay includes a fluorescently labeled anti-BrdU 
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antibody, to amplify the readout signal (which is produced by the added terminal 
deoxynucleotidyl transferase).  
A consequence of seizures is excitotoxicity. Pathologically high cytosolic Ca2+ 
transients ([Ca2+]i), caused by overexcitation of neurons, activate proteases such as Ca2+-
dependent calpains, which are one cause of cellular injury and death. To verify calpain 
activation, we assayed brain regions for the cleavage of spectrin, a known calpain substrate 
in the hippocampus and elsewhere in the brain. We observed a striking increase in the amount 
of spectrin cleavage (Fig. 4.9A) in TM-treated Ate1flox/-;CaggCreER mice under KA 
treatment, in comparison with  KA-treated wild-type mice (lane 2 and 4 versus lane 3 and 5 
in Fig. 4.9 A).  
 
Future Experiments  
Our findings about the strong and apparently connection between the Ate1-mediated 
N-terminal aginylation and the propensity toward (as well as severity of) epileptic seizures 
indicate a major role of the Arg/N-end rule pathway as a suppressor of overexcitation and 
epilepsy. Mice that were made Ate1-deficient (TM-treated Ate1flox/-;CaggCreER mice and 
Ate1tetO/- mice fed a Dox-deficient diet) suffered more severe seizures, neuronal death, and 
elevated intracellular calpain activity. One advantage of Ate1tetO/-;R26rtTA mice (in which 
one copy of Ate1 gene is unconditionally null while the other copy expresses Ate1 only in 
the presence of Dox) is the ability to reverse Ate1-deficiency through feeding these mice a 
Dox-containing diet. We intend to see whether a reversal of Ate1 deficiency in these mice 
would alleviate their epileptic phenotype. Furthermore, a plausible explanation for the bulk 
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of our observations about the connection between the Arg/N-end rule pathway and 
epilepsy is that these striking phenotypes of Ate1-deficient mice are caused at least in part 
by abnormally high steady-state levels of Rgs4, Rgs5, and Rgs16 G-protein regulators in  
these mice, as these RGS proteins are conditionally short-lived owing to their nitric 
oxide/oxygen-dependent, Ate1-dependent degradation by the Arg/N-end rule pathway [87, 
129]. If so, a down-regulation or complete ablation of, for example, Rgs4 (the most 
prominently and broadly expressed RGS among the above three proteins) may at least 
partially rescue the above phenotypes of Ate1-deficient mice.  
We are collaborating with the Neubig group [130-135] in testing their small-
compound Rgs4 inhibitor with our Ate1-deficient mouse strains. We have recently received 
the CCG-203769 RGS4 inhibitor from Dr. Neubig and are about to initiate these 
experiments. We also are constructing, through compound heterozygous matings, double-
mutant Ate1flox/- Rgs4-/-; CaggCreER mice that unconditionally lack Rgs4 and can be caused 
to ablate their remaining copy of the Ate1 gene. Behavioral and histological assays with the 
above drug-treated mice and with double-mutant mice (vis-à-vis controls) will further 
advance the mechanistic understanding of epilepsy and the role of Ate1-Rgs4 circuits in the 
control of neuronal excitation. 
A major aspect of epilepsy is over-activation of calpain proteases. Such activation 
generates, in vivo, many intracellular protein fragments. As discussed above and shown by 
earlier studies in our lab [111], a large fraction of such fragments are natural substrates of the 
Arg/N-end rule pathway, and, in particular, of its Ate1-dependent arginylation branch. We 
shall, therefore, continue to address this aspect of abnormal phenotypes of Ate1-deficient 
mice, in part by applying mass-spectrometry (MS)-based methods such as PROTOMAP, 
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which makes it possible to detect and measure the in vivo generation of protein fragments 
[136]. 
In sum, the long-term aim of these ongoing studies is a more detailed understanding 
of the role of the Arg/N-end rule pathway as a regulator of epilepsy-relevant circuits as well 
as a broader set of functions of this proteolytic pathway in the brain. 
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Materials and Methods 
Animal Care and Treatments 
All animal procedures (protocol #1328) were done with approval by the Institutional Animal 
Care and Use Committee (IACUC) and the Office of Laboratory Animal Research (OLAR) 
at the California Institute of Technology. Mice were housed at 71-75º F (22-24º C), 30-70% 
humidity, and 13 hours light / 11 hours dark cycle. Mice were either kept either in elevated-
barrier, in intermediate-barrier, or in low-barrier facilities depending on specific procedures. 
Mice were fed with PicoLab® Rodent Diet 20 5053 (LabDiet St. Louis, MO) ad libitum. 
 
Ate1flox/-;CaggCreER Mouse Strains  
Ate1flox/-;CaggCreER mice were constructed previously [121]. The mice harbored 
one unconditionally null Ate1− allele (derived, through matings, from the previously 
constructed heterozygous Ate1+/− mice bearing an unconditionally null Ate1− allele [120]) 
and one “floxed” (lox sites-bearing), conditionally active Ate1flox allele that could be made 
null in the presence of active Cre recombinase. These mice also contained the CaggCreER 
gene, expressed from the ubiquitously active chimeric Cagg promoter [137]. CaggCreER 
encoded CreER, a fusion between the phage P1 Cre recombinase and a derivative of the 
mouse estrogen receptor ligand-binding domain. CreER was functionally inactive 
(sequestered in the cytosol) but could be activated by intraperitoneal (IP) injection of 
tamoxifen (TM).  
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Mice aged between 3 and 8 weeks were treated at 1 mg/g of body weight (BW) 
dosage with TM (Sigma) (2 mg in 0.2 ml sesame oil) by daily IP injections over 5 days. Mice 
were weighed weekly, starting 3 days before the first TM treatment.  
To produce Ate1flox/−;CaggCreER mice, we mated Ate1flox/+ mice with 
Ate1+/−;CaggCreER mice (the latter were generated by mating Ate1+/− with 
Ate1+/+;CaggCreER mice). To produce Ate1flox/flox;CaggCreER mice, we mated 
Ate1flox/+ mice with Ate1flox/+;CaggCreER mice (the latter were generated by mating 
Ate1flox/+ mice with Ate1+/+;CaggCreER mice). 
 
Construction of Ate1tetO/- and Ate1tetO/-;R26rtTA Mouse Strains 
The targeting vector was constructed using a DNA fragment between the BstXI and 
PacI restriction sites on the Ate1 gene locus. This fragment encompasses Ate1 exon 1A and 
exon 1B, with the bidirectional PAte1 promoter in between the two exons [121]. The fragment 
was modified as follows. A hygromycin resistance marker, Hph, expressed from the PPGK 
promoter and terminated with a polyA tail was inserted upstream of the Ate1 exon 1B 
between the XbaI and XhoI restriction sites. The marker was flanked by two loxP sites. The 
(TetO)7 PminiCMV promoter replaced the bidirectional PAte1 promoter next to the StuI restriction 
site.  
The targeting vector was electroporated into 129 embryonic stem (ES) cells.  The 
resulting cell population was plated on hygromycin-containing plates to select for 
hygromycin-resistant ES cell colonies. ES cells were grown in DMEM supplemented with 
15% fetal bovine serum (FBS), 0.1 mM non-essential amino acids, 0.1 mM β-
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mercaptoethanol, 2 mM glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 1 mM 
pyruvate, and 1,000 U/ml leukemia inhibitory factor (LIF) [138], using a feeder layer of 
hygromycin-resistant mouse primary fibroblasts that had been treated with 10 µg/ml 
mitomycin C for 3 hr at 37°C. Selection with hygromycin (at 0.2 mg/ml) was started 24 hr 
after electroporation. Correctly targeted ES cell clones were identified using Southern 
hybridization and PCR. 
ES cell lines that had apparently normal karyotypes were injected into 3.5-day-
postcoitum C57BL/6J blastocysts and implanted into pseudopregnant females. The resulting 
male chimeric offspring were mated with C57BL/6J females. In some of the progeny, Ate1tetO 
containing ES cells became a part of germline [138, 139]. Mice with the correctly integrated 
Ate1tetO allele were mated with Cre-expressing mice to remove the Hph marker, thereby 
producing the desired Ate1tetO/+ mice. The loss of the resistance marker was checked by 
Southern DNA hybridization and by PCR as well. Ate1tetO/+ mice were mated with the 
Gt(ROSA)26Sortm1(rtTA2S*M2)Whsu (R26rtTA) mice obtained from the Jackson Laboratory [123]. 
R26rtTA mice express a modified form of reverse tetracycline/doxycycline (Dox)-controlled 
transactivator (rtTA) at the Rosa26 locus. rtTA is a fusion of a TetR mutant (rTetR) and the 
C-terminal activation domain of VP16 of the herpes simplex virus [124]. The R26rtTA allele 
allows the overexpression of Ate1 from the Ate1tetO allele upon addition of Dox in food. 
To produce Ate1tetO/- mice, Ate1tetO/+ mice were mated with Ate1+/- mice [120]. To 
produce Ate1tetO/tetO mice, Ate1tetO/+ mice were mated with Ate1tetO/+ mice. To produce 
Ate1tetO/-;R26rtTA, Ate1tetO/+;R26rtTA, and Ate1tetO/tetO;R26rtTA mice, Ate1tetO/- mice, 
Ate1tetO/+ mice, and Ate1tetO/tetO mice were mated with R26rtTA mice respectively. During the 
mating, pregnant female mice that carried litters containing Ate1tetO/-;R26rtTA, 
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Ate1tetO/+;R26rtTA, or Ate1tetO/tetO;R26rtTA mice were fed ad libitum with Dox-containing 
diet TD.00502 (Envigo). The Dox-containing diet dosage is 0.5-0.9 mg of Dox per 3-5 g of 
food. The daily food intake of a 30-g BW adult mice is about 3-5 g of food giving the 
pregnant mice the daily dosage of 0.5-0.9 mg of Dox [140]. All other mice were fed with the 
control Dox-deficient diet 2018 (Envigo).  
 
Construction of Ate1flox/- Rgs4-/-; CaggCreER Mouse Strains 
The previously constructed Rgs4-/- mice were a gift from Dr. Scott Heximer 
(University of Toronto, Canada) [95]. The functional null Rgs4- allele, termed Rgs4tm1Dgen in 
the Jackson Laboratory database, was generated by Deltagen Inc. That allele was produced 
by a targeted insertion of the lacZ gene and the neomycin (Neo) marker. LacZ transcription 
was driven by the endogenous Rgs4 promoter. Rgs4-/- mice are healthy with no apparent 
defect.  
To produce Ate1flox/- Rgs4-/-; CaggCreER mice, appropriate mating pairs were made 
between Rgs4-/- mice and Ate1flox/-; CaggCreER mice. Ate1flox/- Rgs4-/-; CaggCreER mice 
aged between 3 and 8-week old were treated with TM (Sigma) (2 mg in 0.2 ml sesame oil) 
by daily IP injections over 5 days. Mice were weighed weekly, starting 3 days before the first 
TM treatment.  
 
Genotyping of Mouse Strains 
Mouse tails and ears were digested overnight at 60oC in “tail digestion buffer” (5 mM 
EDTA pH 8.0, 0.2 M NaCl, 0.3% SDS, 0.4 mg/ml Proteinase K, 0.1 M Tris-HCl pH 8.5). 
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Genomic DNA was precipitated using isopropanol and cleaned with 70% ethanol [121]. 
Genomic DNA was dissolved in “TE buffer” (1 mM EDTA, 10 mM Tris-HCl, pH 8.0). 
Specific gene alleles were verified by PCR using primers listed in Table 4.2. All PCR 
reactions except for those to detect the CaggCreER transgene were carried out using HotStar 
Taq DNA polymerase, standard buffer conditions (Qiagen), 35 cycles of template 
denaturation for 30 seconds at 95°C, followed by primer annealing for 30 seconds at 60°C 
and primer extension for 1 minute at 72°C. PCR reactions for detecting CaggCreER were 
carried out using 30 cycles of template denaturation for 30 seconds at 95°C, followed by 
primer annealing for 30 seconds at 58°C and primer extension for 45 seconds at 72°C. 
 
Seizure Induction by Kainate (KA) or NMDA Injection 
Mice at indicated ages were injected intraperitoneally (injection volume 100-300 µl) 
with either 20-40 mg/kg body weight BW of KA (Sigma K0250; 2 mg/ml in 0.9% saline) or 
80-120 mg/kg BW of NMDA (Sigma M3262; 20 mg/ml in 0.9% saline). Mice were scored 
at 1 min intervals using a Racine scale (Table 4.3) for 60-120 min [141-143]. The mean and 
the standard error of the mean (SEM) were calculated for each test group.  
Once the observations were completed, mice were sacrificed for analyses or returned 
to their cages. For mice that experienced high levels of seizure, diazepam was injected to 
calm them before returning them to their cages. If the seizure could not be controlled, mice 
were euthanized. 
 
Tissue Extracts and Immunoblotting 
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 Mouse tissues were harvested and lysed in “NP-40 buffer” (150 mM NaCl, 1% 
NP-40, 50 mM Tris-HCl, pH 8.0) or in “RIPA buffer” (150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 8.0). Buffers were supplemented 
with 1 mM dithiothreitol (DTT) and freshly dissolved “Complete EDTA-Free Protease 
Inhibitors” (Roche-05892953001). Tissues were disrupted using the MP FastPrep-24 
instrument and Lysing Matrix D (MP Biomedicals) with 2 or 3 runs at 6.5 m/s for 25 sec 
each, and with 5 min incubations on ice between the runs. The lysates were clarified by 
centrifugation at 12,000g for 30 min at 4°C.  
The lysates were subjected to gel electrophoresis using MES or MOPS buffer and 
Bis-Tris SDS-PAGE gels with the appropriate gel percentage (10%, 12%, or 4-12%). The 
proteins were transferred to either PVDF or nitrocellulose membrane using the iBlot® Dry 
Blotting System (ThermoFisher Scientific). Immunoblots were detected using the IRDye® 
Odyssey Imaging Systems (LI-COR). 
 
In Vitro Arginylation Assay 
The arginyltransferase (R-transferase) reaction (50 µl) contained extracts from a 
specific mouse tissue (2.5 mg of total protein per ml), 0.5 mg/ml α-lactalbulmin (Sigma), 0.6 
mg/ml total E. coli tRNA (Roche 10109541001), 800 U/ml E. coli aminoacyl-tRNA 
synthetase (Sigma A3646), 5 mM MG132, 1 mM ATP, 30 mM KCl, 2 mM MgCl2, 2 mM 
DTT, 10 mM Tris-HCl pH 8.0, and 0.3 mM 3H-arginine (Arg) (PerkinElmer 
NET1123001MC). The reaction mixture was incubated for 30 min at 37oC and was spotted 
onto 1-cm square 3MM Whatman filter papers. The filter papers were boiled for 10 min in 
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10% trichloroacetic acid (TCA). The filter papers were then washed in ice-cold 5%TCA 
three times and in ice-cold ethanol once. Incorporated hot TCA-insoluble 3H-Arg was 
measured using a Beckman LS 6500 Scintillation Counter [144].  
 
Analyses of Tissue Sections 
48 hr after seizure induction, mice were fixed through transcardial perfusion with 4% 
formaldehyde (Electron Microscopy Sciences). Mouse brains were further fixed with 4% 
formaldehyde for 16 hr, rinsed once with PBS for 10 min, dehydrated in 15% Sucrose-PBS 
for 12 hr, and dehydrated again in 20% Sucrose-PBS for 12 hr. Tissues were thereafter frozen 
in Tissue-Tek O.C.T Compound (Sakura Finetek) using 70% ethanol-dry ice bath and stored 
at -80oC. Frozen tissues were sectioned coronally into sections (12 μm or 20 μm).  
The 12 μm sections were mounted on Superfrost Plus Microscope Slides (Fisher 
Scientific). They were used to assess apoptosis by TUNEL, a nuclear DNA fragmentation 
assay, using a TUNEL kit (Roche, Indianapolis, IN), fluorescein-dUTP, and manufacturer's 
instructions.  
The 20 μm sections were mounted onto 1% gelatin coated glass slides. They were 
used to assess cell death using Fluoro-Jade C staining (Histo-Chem Inc). Fluoro-Jade C is a 
mixture of the sulfate ester of trisodium 5-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzene, 
1,2,4, tricarboxylic acid, disodium 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(2,4-
dihydroxybenzol) terephthalic acid, and disodium 2,5-bis(6-hydroxy-3-oxo-3H-xanthen-9-
yl) terephthalic acid. Fluoro-Jade C reproducibly and specifically stains degenerating 
neurons through an unknown mechanism [127]. 
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Figure 3.1 Regulation of gene expression by doxycycline (Dox). The R26rtTA mice express a 
modified form of reverse tetracycline/Dox-controlled transactivator (rtTA) whose gene is integrated 
in the Rosa26 locus [123]. rtTA is a fusion of a TetR mutant (rTetR) and the C-terminal activation 
domain of VP16 of the herpes simplex virus [124]. Upon the addition of Dox, rTetR undergoes 
conformation change and binds to the tetO DNA elements [125]. The activation domain of VP16 
attracts host transcription factors and RNA polymerase II to initiate transcription [126]. 
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Figure 3.2 Mouse Ate1 alleles. The wild-type, Ate1-, Ate1flox, and Ate1tetO alleles are shown. The 
differences between these alleles are confined to the region between Ate1 exon 1A and exon 5. (A) 
A diagram of the 5’ end of wild-type Ate1 allele shows the bidirectional endogenous PAte1 promoter 
being flanked by the Ate1 exon 1A and exon 1B [144]. (B) For Ate1- allele, the NLS-containing lacZ 
(NLS-lacZ) and the neomycin (Neo) selection marker expressed from the phosphoglycerate kinase 
PPGK promoter (PGK/Neo) replaced Ate1 exon 1B, exon 2, exon 3, and the corresponding introns 
[120]. (C) For the Ate1flox allele, loxP sites were inserted before exon 2 and after exon 4 [121]. For 
the Ate1tetO allele, the (TetO)7 PminiCMV promoter replaced the endogenous bidirectional element of 
the PAte1 promoter. There is an additional loxP site upstream of Ate1 exon 1A that resulted from the 
removal of the hygromycin resistance marker that had been used, earlier, to insert the new (TetO)7 
PminiCMV promoter element. 
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Figure 3.3 Dox induces Ate1 in Ate1tetO/tetO;R26rtTA and Ate1tetO/+;R26rtTA mice. Lysates from 
the stomachs and the pancreas of Ate1tetO/tetO;R26rtTA and Ate1tetO/+;R26rtTA mice were fractionated 
with 4-12% SDS-PAGE gels and immunoblotted against anti-Ate1. In extracts from the stomachs 
(lanes 1-4) and pancreas (lanes 5-6) of Ate1tetO/tetO;R26rtTA and Ate1tetO/+;R26rtTA mice, Ate1 R-
transferase was expressed above its normal endogenous levels when mice were fed a Dox-containing 
diet. The corresponding total protein patterns (Ponceau S-stained) are shown in lanes 9-16. 
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Figure 3.4 Ate1tetO/- mice are Ate1 R-transferase deficient. Ate1tetO/- mice and the control wild-
type (Ate1+/+) littermates were fed with Dox-deficient diet. (A) Lysate from embryonic fibroblast 
(EF) cell lines from Ate1+/+ and Ate1-/- embryos (lane 1-2) and from the brain, liver, testis, heart, the 
pancreas of Ate1+/+ or Ate1tetO/- mice (lane 3-16) were fractionated with 4-12% SDS-PAGE gels and 
immunoblotted against anti-Ate1. Ate1tetO/- mice that were on Dox-deficient diet lacked 
immunologically detectable levels of Ate1 R-transferase on all examined tissues. The only 
exception, among the examined tissues, was the thymus, which contained a below-wild-type but 
significant amount Ate1. (B) The above fractionated lysates were also immunoblotted against anti-
Rgs4 (lane 17-32). In the brain, the reduction in protein level of Ate1 R-transferase in Ate1tetO/- mice 
was accompanied by a marked increase in the level of the Rgs4 protein, conditionally short-lived 
protein and an Nt-arginylation substrate of Ate1 (compare between lanes 3 and 4 and between lanes 
19 and 20). 
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Figure 3.5 Increased epileptic tendency and seizure severity in Ate1-deficient (Ate1tetO/-) mice 
versus control wild-type and heterozygous littermates (Ate1tetO/+ mice, Ate1+/- mice, and 
Ate1tetO/+;R26rtTA mice) upon NMDA injection. Ate1tetO/- mice and Ate1tetO/-;R26rtTA mice were 
fed with Dox-deficient diet to ensure Ate1-deficiency. 8 control wild-type and heterozygous mice 
and 6 Ate1tetO/- or Ate1tetO/-;R26rtTA mice were used for the study. The NMDA treated mice were 
232 to 268-day old. They received a single NMDA IP injection at 85 mg/kg of BW, followed by 
observations over 1 hr. Seizure severity was scored using a Racine scale. The mean and the standard 
error of the mean (SEM) were plotted. 
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Figure 3.6 Increased epileptic tendency and seizure severity (Ate1-/-) mice versus wild-type 
(Ate1+/+) and heterozygous (Ate1+/-) littermates upon KA injection. 3 control wild-type and 6 
Ate1flox/-;CaggCreER mice were used for the study. Ate1flox/-;CaggCreER mice were made Ate1-
deficient (Ate1-/-) through TM treatment [121]. The KA-treated mice were of 60 to120-day old. They 
received a single KA IP injection at 20 mg/kg of body weight (BW), followed by observations over 
the next hour. Seizure severity was scored using Racine scale. The mean and the standard error of 
the mean (SEM) were plotted. 
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Figure 3.7. Extensive neuron death in KA-treated Ate1-deficient (Ate1-/-) mice but not in 
identically treated wild-type (Ate1+/+) mice. Ate1flox/-;CaggCreER mice were made Ate1-deficient 
(Ate1-/-) through TM treatment. (A) Fluoro-Jade C (FJC) and DAPI staining for Ate1-/- mice and the 
corresponding Ate1+/+ littermates in the hippocampus region. (B) FJC and DAPI staining for Ate1-/- 
mice and the corresponding Ate1+/+ littermates in the thalamus region (C) FJC and DAPI staining 
for Ate1-/- mice and the corresponding Ate1+/+ littermates in the hypothalamus region. (D) The 
approximate field of visualization for each hippocampus, thalamus, and hippocampus region. (Image 
credit: Allen Institute) 
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Figure 3.8 Increase apoptosis in hippocampus, thalamus, and hypothalamus in KA-treated 
Ate1-deficient (Ate1-/-) mice but not in identically treated wild-type (Ate1+/+) mice. Ate1flox/-
;CaggCreER mice were made Ate1-deficient (Ate1-/-) through TM treatment. (A) TUNEL labeling 
and DAPI staining for Ate1-/- mice and the corresponding Ate1+/+ littermates in the hippocampus 
region. (B) TUNEL labeling and DAPI staining for Ate1-/- mice and the corresponding Ate1+/+ 
littermates in the thalamus region (C)  TUNEL labeling and DAPI staining for Ate1-/- mice and the 
corresponding Ate1+/+ littermates in the hypothalamus region. 
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 Figure 3.9 Elevated calpain activation in KA-treated Ate1-deficient (Ate1-/-) mice. Ate1flox/-
;CaggCreER mice were made Ate1-deficient (Ate1-/-) through TM treatment. Lysates from the 
hippocampus were fractionated with 4-12% SDS-PAGE gels and immunoblotted against (A) anti-
Spectrin, (B) anti-Ate1, and (C) anti-GAPDH. In KA-treated Ate1-/- mice, the amount of  spectrin 
cleavage was greatly elevated compare to KA-treated wild-type (Ate1+/+) mice (lanes 2 and 4 versus 
lanes 3 and 5 in Fig. 4.9 A). anti-Ate1 and anti-GAPDH immunoblots were shown to verify Ate1-
deficiency and similar loading inputs.  
 
 
 
 
 
 
 
 
  
140
Table 3.1 The GPCRs in synaptic transmissions 
Gα proteins Glutamate GABA ATP Adenosine 
Gαi/o mGluR2, 3, 4, 6, 7, 8 GABAB P2YR12, 13, 14 A1, A3 
Gαq/11 mGluR1, 5  P2YR1, 2, 4, 6, 11  
Gαs   P2YR11 A2A, A2B 
The GPCRs in synaptic transmissions and their corresponding Gα proteins. There are three major 
family of Gα proteins: Gαi/o, Gαq/11, and Gαs. The major neurotransmitters in synaptic transmissions 
include glutamate which activates the mGluRs, GABA which activates the GABAB receptor, ATP 
which activates the P2YRs, and adenosine which activates the A receptors [32, 67]. 
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Table 3.2 PCR Primers 
Allele Primer Size (bp) 
CaggCreER GTTCGCAAGAACCTGATGGACA; 
CTAGAGCCTGTTTTGCACGTTC  
Cre: 320 
Ate1- GGTATTTGCTGCCGTCCTTTGGTGGT;
CTGTTCCACATACACTTCATTCTCAG;
CTGGAGACAAAGCCCCAGCCAGAC  
Wild-type: 300; 
Ate1 null: 560 
Ate1flox CAAGCAGGGGAAGGAGGC; 
TTCAGGAGTTAGCCATTGCC 
Wild-type: 368; 
Ate1 flox: 408 
Ate1tetO ACACGCCTACCTCGACCCGGG; 
CCGAGACGCACCCCTGCAACC; 
TACCCCCTAGGGAGGGCGAGG 
Wild-type: 400; 
Ate1 tet: 609 
Ate1floxOFF GTTTGTGTCACCACTCCTACC 
TTCAGGAGTTAGCCATTGCC 
Ate1 flox-OFF: 470 
Rgs4- GGGCCAGCTCATTCCTCCCACTCAT 
GGACATGAAACATCGGCTGGGGTTC 
CCATCTTGACCCAAATCTGGCTCAG 
Wild-type: 441 
Rgs4 null: 225 
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Table 3.3 Racine scale  
Scale Behaviors Severity Error 
0 no behavior alteration   
1 immobility, mouth and facial movements, facial clonus Discomfiture Sleeping 
2 head nodding, forelimb and/or tail extension, rigid 
posture 
3 forelimb clonus, repetitive movements Mild seizure Grooming 
4 rearing, forelimb clonus with rearing, rearing and 
falling 
Seizure 
5 continuous rearing and falling, jumping  
6 severe tonic-clonic seizures  
7 death   
Racine scale with the corresponding behaviors and severities of seizures. Very mild epileptic 
episodes can be misinterpreted as normal mouse behaviors, such as sleeping or grooming.  
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